0001607062-18-000172.txt : 20180515 0001607062-18-000172.hdr.sgml : 20180515 20180515145513 ACCESSION NUMBER: 0001607062-18-000172 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180515 DATE AS OF CHANGE: 20180515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iGambit, Inc. CENTRAL INDEX KEY: 0001479681 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 113363609 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-53862 FILM NUMBER: 18835591 BUSINESS ADDRESS: STREET 1: 1050 W JERICHO TURNPIKE STREET 2: SUITE A CITY: SMITHTOWN STATE: NY ZIP: 11788 BUSINESS PHONE: 631-670-6777 MAIL ADDRESS: STREET 1: 1050 W JERICHO TURNPIKE STREET 2: SUITE A CITY: SMITHTOWN STATE: NY ZIP: 11788 10-Q 1 igmb033118form10q.htm FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Quarterly period ended March 31, 2018

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from to

Commission file number 000-53862

iGambit Inc.

(Exact name of small business issuer as specified in its charter)

Delaware		11-3363609
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

1050 W. Jericho Turnpike, Suite A
Smithtown, New York 11787
(Address of Principal Executive Offices) (Zip Code)

(631) 670-6777
(Issuer’s Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):


Large accelerated filer ☐	Accelerated filer ☐	Non-accelerated filer ☐	Smaller reporting company ☒
		(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

As of May 15, 2018 there were 125,089,324 (not including 10 million shares held in treasury) shares of the Registrant’s $0.001 par value common stock outstanding.

iGambit Inc.
Form 10-Q

	Page No.
Part I — Financial Information
Item 1. Financial Statements:
Condensed Consolidated Balance Sheets	3
Condensed Consolidated Statements of Operations	4
Condensed Consolidated Statements of Cash Flows	5
Notes to Condensed Consolidated Financial Statements	6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	23
Item 3. Quantitative and Qualitative Disclosures About Market Risk	26
Item 4. Controls and Procedures	27

Part II — Other Information
Item 1. Legal Proceedings	27
Item 1A. Risk Factors	27
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	27
Item 3. Defaults upon Senior Securities	27
Item 4. Removed and Reserved	27
Item 5. Other Information	27
Item 6. Exhibits	28

PART I – FINANCIAL INFORMATION

Item 1 – Financial Statements

IGAMBIT INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)

	MARCH 31,			DECEMBER 31,
	2018			2017
ASSETS
Current assets
Cash	$	60,245		$	9,449
Accounts receivable		1,521			6,254
Prepaid expenses and other current assets		22,521			39,377
Total current assets		84,287			55,080

Other assets
Property and equipment, net		3,413			3,845
Intangible assets, net		3,093,918			3,267,885
Deposits		1,945			1,945
	$	3,183,563		$	3,328,755

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable and accrued expenses	$	295,593		$	348,354
Accrued interest on notes payable		18,775			21,602
Amounts due to related parties		128,476			128,476
Deferred revenue		5,375			9,100
Notes payable		52,500			52,500
Convertible debentures, net		560,799			333,689
Derivative liability		—			66,059
Total current liabilities		1,061,518			959,780

Stockholders' equity
Preferred stock, $.001 par value; authorized - 100,000,000 shares; issued and outstanding - 0 shares in 2017 and 2016, respectively		—			—
Common stock, $.001 par value; authorized - 400,000,000 shares; 132,290,751 and 126,196,571 shares issued and 122,290,751 and 116,196,571 shares outstanding (net of treasury shares) as of March 31, 2018 and December 31, 2017, respectively		132,291			126,196
Additional paid-in capital		13,248,356			12,891,348
Accumulated deficit		(10,258,602	)		(9,648,569	)
		3,122,045			3,368,975
Less: Treasury stock; 10,000,000 shares, at cost		(1,000,000	)		(1,000,000	)
Total stockholders' equity		2,122,045			2,368,975
	$	3,183,563		$	3,328,755

See accompanying notes to the condensed consolidated financial statements.

IGAMBIT INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
THREE MONTHS ENDED MARCH 31,
(UNAUDITED)

		2018			2017
Sales	$	4,192		$	4,350
Cost of sales		7,930			180

Gross profit (loss)		(3,738	)		4,170

Operating expenses
General and administrative expenses		234,264			167,380
Amortization		173,967			—
Total operating expenses		408,231			167,380
Loss from operations		(411,969	)		(163,210	)

Other income (expenses)
Interest income		—			—
Change in fair value of derivative liability		(118,101	)		—
Loss on extinguishment of debt		(63,699	)		—
Interest expense		(16,264	)		(11,927	)
Total other income (expenses)		(198,064	)		(11,927	)

Loss from continuing operations		(610,033	)		(175,137	)
Loss from discontinued operations		—			(66,937	)
Net loss	$	(610,033	)	$	(242,074	)


Basic and fully diluted loss per common share:
Continuing operations	$	(.01	)	$	(.00	)
Discontinued operations	$	(.00	)	$	(.00	)
Net loss per common share	$	(.01	)	$	(.00	)

Weighted average common shares outstanding - basic and fully diluted		121,245,294			48,807,434

See accompanying notes to the condensed consolidated financial statements.

IGAMBIT INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
THREE MONTHS ENDED MARCH 31,
(UNAUDITED)

		2018			2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(610,033	)	$	(242,074	)
Loss from discontinued operations		—			66,937
Net loss from continuing operations		(610,033	)		(175,137	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		432			213
Amortization		173,967			12,745
Non cash interest expense		15,527			11,031
Stock-based compensation expense		—			800
Loss on extinguishment of debt		63,699			—
Change in fair value of derivative liability		118,101			—
Changes in operating assets and liabilities:
Accounts receivable		4,733			(1,250	)
Prepaid expenses and other current assets		16,856			17,492
Accounts payable and accrued expenses		(52,761	)		18,366
Deferred revenue		(3,725	)		—
Net cash used in continuing operating activities		(273,204	)		(115,740	)
Net cash used in discontinued operating activities		—			(8,975	)
NET CASH USED IN OPERATING ACTIVITIES		(273,204	)		(124,715	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Preacquisition loans to subsidiary		—			(50,000	)
Cash acquired from acquisition of subsidiary		—			29,584
Net cash used in continuing investing activities		—			(20,416	)
Net cash provided by discontinued investing activities		—			31,636
NET CASH PROVIDED BY INVESTING ACTIVITIES		—			11,220

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible debt		309,000			100,000
Proceeds from sale of common stock		15,000			100,000
Proceeds from related party loans		—			492
Net cash provided by continuing financing activities		324,000			200,492
Net cash used in discontinued financing activities		—			(23,992	)
NET CASH PROVIDED BY FINANCING ACTIVITIES		324,000			176,500

NET INCREASE IN CASH		50,796			63,005
CASH - BEGINNING OF PERIOD		9,449			10,522
CASH - END OF PERIOD	$	60,245		$	73,527

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the period for:
Interest	$	737		$	896

Non-cash investing and financing activities:
Debt discount related to derivative liability	$	43,249		$	80,822
Notes payable converted to common stock		102,000			—
Common stock issued in payment of accrued interest		12,346			—

See accompanying notes to the condensed consolidated financial statements.

IGAMBIT INC.

Notes to Condensed Consolidated Financial Statements

Three Months Ended March 31, 2018 and 2017

(Unaudited)

Note 1 - Organization and Basis of Presentation

The consolidated financial statements presented are those of iGambit Inc., (the “Company”) and its wholly-owned subsidiaries, HealthDatix, Inc. (“HealthDatix”), Wala, Inc. doing business as Arcmail Technology (“ArcMail”) and Gotham Innovation Lab Inc. (“Gotham”). The Company is a holding company which seeks out acquisitions of operating companies in technology markets. HealthDatix, Inc. is engaged in the business of streamlining the process of managing information in the document-intensive medical field for customers throughout the United States. ArcMail provides email archive solutions to domestic and international businesses through hardware and software sales, support, and maintenance. Gotham was in the business of providing media technology services to real estate agents and brokers in the New York metropolitan area.

Interim Financial Statements

The following (a) condensed consolidated balance sheet as of December 31, 2017, which has been derived from audited financial statements, and (b) the unaudited condensed consolidated interim financial statements of the Company have been prepared in accordance with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2018 are not necessarily indicative of results that may be expected for the year ending December 31, 2018. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”) on April 17, 2018.

Business Acquisition

On February 14, 2017, the Company acquired Healthdatix, Inc., formerly known as HubCentrix, Inc. in accordance with a stock purchase agreement. Previously, the Company was focused on the technology markets. The Company has tailored its strategy to focus on pursuing specific medical technology strategies and objectives. The acquisition of HealthDatix, provides the Company with its first medical technology, WellDatix, a proprietary platform that enables physicians to identify patients eligible for Annual Wellness Visits which are reimbursed by Medicare. This technology positions the Company to participate in the anticipated accelerated market needs of the physician community throughout the country. Pursuant to the stock purchase agreement, the total consideration paid for the outstanding capital stock of HealthDatix was $1,050,000 consisting of 15,000,000 shares of iGambit restricted common stock, valued at $.07 per share.

The results of operations of HealthDatix for the period February 14, 2017 to March 31, 2017 have been included in the consolidated statements of operations for the three months ended March 31, 2017. The following table presents unaudited pro forma results of operations of the Company and HealthDatix as if the acquisition had occurred at January 1, 2017. The pro forma condensed financial information is presented for informational purposes only. The unaudited pro forma results of operations are not necessarily indicative of results that would have occurred had the acquisition taken place at the beginning of the earliest period presented, or of future results.

	March 31,
	2017
Pro forma revenue	$	7,600
Pro forma gross profit	$	7,413
Pro forma loss from operations	$	(187,172	)
Pro forma net loss	$	(199,099	)

On April 5, 2017, the Company, through its wholly owned subsidiary HealthDatix, Inc. (“HealthDatix”) consummated the acquisition of certain assets of the CyberCare Health Network Division from EncounterCare Solutions Inc. (ECSL) in accordance with an Asset Purchase Agreement (the “Agreement”) by and among, HealthDatix, ECSL and the Company. Pursuant to the Agreement, ECSL will sell, convey, transfer and assign to HealthDatix certain assets (the “Assets”), and HealthDatix will purchase and accept from the ECSL all right, title and interest in and to the Assets in exchange for sixty million 60,000,000 shares of restricted common stock of iGambit.

Note 2 – Discontinued Operations

Sale of Business

Effective October 1, 2016, management decided to dispose of its subsidiary Arcmail and entered into a letter of intent on March 1, 2017 to sell Arcmail in a stock exchange to the CEO of Arcmail. On June 30, 2017, the Company completed the sale of ArcMail to Rory T. Welch, the CEO of Arcmail (“Welch”) in accordance with a Stock Purchase Agreement (the “Purchase Agreement”) by and between the Company and Welch. Pursuant to the Stock Purchase, the total consideration paid for the outstanding capital stock of ArcMail is remittance of 10,000,000 shares of iGambit common stock previously issued to Welch. As per the Purchase Agreement, the Company’s operations of ArcMail ended March 31, 2017 and Welch’s operation of the business was effective as of April 1, 2017. Arcmail’s operating loss for the three months ended March 31, 2017 has been included in loss from discontinued operations in the statements of operations for the year ended December 31, 2017.

On November 5, 2015, pursuant to an asset purchase agreement Gotham sold assets consisting of fixed assets, client and supplier lists, trade names, software, social media accounts and websites, and domain names to VHT, Inc., a Delaware corporation for a purchase price of $600,000. Gotham received $400,000 and commencing on January 29, 2016, VHT, Inc. shall pay twelve equal monthly installments of $16,667 on the last business day of each month (the “Installment Payments” and each, an “Installment Payment”), each Installment Payment to consist of (1) an earn-out payment of $10,000 (the “Earn-Out Payments” and each, an “Earn-Out Payment”), and (2) an additional payment of $6,667 (the “Additional Payments” and each, an “Additional Payment”); provided that VHT, Inc. shall only be required to make the Earn-Out Payments for as long as it maintains its relationship with Gotham’s major client, unless it is dissatisfied with VHT, Inc. The terms of the installment payments were fulfilled as of December 31, 2016.

The components of loss from discontinued operations presented in the consolidated statements of operations for the three months ended March 31, 2017 are presented as follows:

Sales	$	386,157
Cost of sales		(29,462	)
General and administrative expenses		(326,247	)
Depreciation and amortization		(4,537	)
Interest expense		(92,848	)
Loss from discontinued operations	$	(66,937	)

Note 3 – Summary of Significant Accounting Policies

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, HealthDatix, Inc., Wala, Inc. and Gotham Innovation Lab, Inc. All intercompany accounts and transactions have been eliminated.

Use of Estimates in the Preparation of Financial Statements

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

Fair Value Measurements

The Company adopted the provisions of ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements.

The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 – quoted prices in active markets for identical assets or liabilities

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

The estimated fair value of the derivative liability was calculated using the Black-Scholes option pricing model. The Company uses Level 3 inputs to value its derivative liabilities. The following table provides a reconciliation of the beginning and ending balances for the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains and losses for the three months ended March 31, 2018.

Liabilities:
Balance of derivative liabilities - beginning of period	$	66,059
Issued		43,249
Converted		(227,409	)
Change in fair value of derivative liabilities		118,101
Balance of derivative liabilities - end of period	$	—

Convertible Instruments

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.

Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.

The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.

The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.

Revenue Recognition

iGambit is a holding company and has no sources of revenue.

HealthDatix’s revenues are derived primarily from its Software as a Service (SaaS) offerings that are rendered to healthcare providers. HealthDatix recognizes revenues when the products or services have been provided or delivered, the fees charged are fixed or determinable, HealthDatix and its customers understand the specific nature and terms of the agreed upon transactions, and collectability is reasonably assured.

Arcmail recognizes revenue from product sales when the following four revenue recognition criteria are met: persuasive evidence of an arrangement exists, an equipment order has been placed with the vendor, the selling price is fixed or determinable, and collectability is reasonably assured. Revenues from maintenance contracts covering multiple future periods are recognized during the current periods and deferred revenue is recorded for future periods and classified as current or noncurrent, depending on the terms of the contracts.

Gotham’s revenues were derived primarily from the sale of products and services rendered to real estate brokers. Gotham recognized revenues when the services or products have been provided or delivered, the fees charged are fixed or determinable, Gotham and its customers understood the specific nature and terms of the agreed upon transactions, and collectability was reasonably assured.

Advertising Costs

The Company expenses advertising costs as incurred. Advertising costs from continuing operations for the three months ended March 31, 2018 and 2017 were $0 and $299, respectively.

Cash and Cash Equivalents

For purposes of reporting cash flows, cash and cash equivalents include checking and money market accounts and any highly liquid debt instruments purchased with a maturity of three months or less.

Accounts Receivable

The Company analyzes the collectability of accounts receivable from continuing operations each accounting period and adjusts its allowance for doubtful accounts accordingly. A considerable amount of judgment is required in assessing the realization of accounts receivables, including the creditworthiness of each customer, current and historical collection history and the related aging of past due balances. The Company evaluates specific accounts when it becomes aware of information indicating that a customer may not be able to meet its financial obligations due to deterioration of its financial condition, lower credit ratings, bankruptcy or other factors affecting the ability to render payment.

Inventories

Inventories consisting of finished products are stated at the lower of cost or market and are presented in assets from discontinued operations. Cost is determined on an average cost basis.

Property and equipment and depreciation

Property and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows:

Office equipment and fixtures			5 - 7 years
Computer hardware			5 years
Computer software			3 years
Development equipment			5 years

Amortization

Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows:

Software			5 years
Technology license			5 years
Purchased in process R&D			Indefinite
Customer contracts			10 years

Goodwill

Goodwill represents the excess of assets acquired over liabilities assumed of HealthDatix and the fair market value of the common shares issued by the Company for the acquisition of HealthDatix. In accordance with ASC Topic No. 350 “Intangibles – Goodwill and Other”), the goodwill is not being amortized, but instead will be subject to an annual assessment of impairment by applying a fair-value based test, and will be reviewed more frequently if current events and circumstances indicate a possible impairment. An impairment loss is charged to expense in the period identified. If indicators of impairment are present and future cash flows are not expected to be sufficient to recover the asset’s carrying amount, an impairment loss is charged to expense in the period identified. The Company recorded a full impairment of the Goodwill as of December 31, 2017.

Long-Lived Assets

The Company assesses the valuation of components of its property and equipment and other long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows.

Deferred Revenue

Deposits from customers included in discontinued operations are not recognized as revenues, but as liabilities, until the following conditions are met: revenues are realized when cash or claims to cash (receivable) are received in exchange for goods or services or when assets received in such exchange are readily convertible to cash or claim to cash or when such goods/services are transferred. When such income item is earned, the related revenue item is recognized, and the deferred revenue is reduced. To the extent revenues are generated from the Company’s support and maintenance services, the Company recognizes such revenues when services are completed and billed. The Company has received deposits from its various customers that have been recorded as deferred revenue and presented as current liabilities in the amount of $5,375 and $9,100 as of March 31, 2018 and December 31, 2017, respectively.

Stock-Based Compensation

The Company accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity, which requires the measurement of compensation expense for all share-based compensation granted to employees and non-employee directors at fair value on the date of grant and recognition of compensation expense over the related service period for awards expected to vest. The Company uses the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing model requires the input of highly subjective assumptions including the expected stock price volatility of the Company’s common stock, the risk free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption related to forfeitures of such grants. Changes in these subjective input assumptions can materially affect the fair value estimate of the Company’s stock options and warrants.

Income Taxes

The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.

The Company applies the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the Company’s financial statements. In accordance with this provision, tax positions must meet a more-likely-than-not recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position.

Note 4 – Going Concern

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has disposed of its operating subsidiary, and has an accumulated deficit of $10,258,602, and a working capital deficit of $977,231 at March 31, 2018. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The Company’s continuation as a going concern is dependent upon its ability to obtain necessary equity financing and ultimately from generating revenues from its newly acquired subsidiary to continue operations. The Company expects that working capital requirements will continue to be funded through a combination of its existing funds and further issuances of securities. Working capital requirements are expected to increase in line with the growth of the business. Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund operations over the next twelve months. The Company has no lines of credit or other bank financing arrangements.

The Company has financed operations to date through the proceeds of a private placement of equity and debt instruments. In connection with the Company’s business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses. The Company intends to finance these expenses with further issuances of securities, and debt issuances. Thereafter, the Company expects it will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to current stockholders. Further, such securities might have rights, preferences or privileges senior to common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, the Company may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict business operations.

The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 5 – Property and Equipment

Property and equipment are carried at cost and consist of the following at March 31, 2018 and December 31, 2017:

	2018		2017
Office equipment and fixtures	$	10,964	$	10,964
Less: Accumulated depreciation		7,551		7,119
	$	3,413	$	3,845

Depreciation expense of $432 and $213 was charged to continuing operations for the three months ended March 31, 2018 and 2017, respectively.

Depreciation expense of $0 and $4,538 was charged to discontinued operations for the three months ended March 31, 2018 and 2017, respectively.

Note 6 – Intangible Assets

Intangible assets from the acquisitions of HealthDatix and ECSL are carried at cost and consist of the following at March 31, 2018 and December 31, 2017:

	2018		2017		Life
Software	$	156,925	$	156,925		5 years
Customer contracts		644,846		644,846		10 years
FDA 510K clearance		1,396,000		1,396,000		5 years
Technology license		1,000,000		1,000,000		5 years
In process research and development		604,000		604,000		Indefinite
		3,801,771		3,801,771
Less: Accumulated amortization		707,853		533,886
	$	3,093,918	$	3,267,885

Amortization expense of $173,967 and $12,745 was charged to continuing operations for the three months ended March 31, 2018 and 2017, respectively.

Note 7 - Loss Per Common Share

The Company calculates net income (loss) per common share in accordance with ASC 260 “Earnings Per Share” (“ASC 260”). Basic and diluted net earnings (loss) per common share was determined by dividing net earnings (loss) applicable to common stockholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options and common stock warrants, have not been included in the computation of diluted net loss per share for the three months ended March 31, 2018 and 2017 as the result would be anti-dilutive.

	Three Months Ended
	March 31,
	2018		2017
Stock options		8,463,000		663,000
Stock warrants		1,150,000		400,000
Total shares excluded from calculation		9,613,000		1,063,000

Note 8 – Stock Based Compensation

Options

In 2006, the Company adopted the 2006 Long-Term Incentive Plan (the "2006 Plan"). Awards granted under the 2006 Plan have a ten-year term and may be incentive stock options, non-qualified stock options or warrants. The awards are granted at an exercise price equal to the fair market value on the date of grant and generally vest over a three or four year period. The Plan expired on December 31, 2009, therefore as of December 31, 2016, there was no unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2006 plan.

The 2006 Plan provided for the granting of options to purchase up to 10,000,000 shares of common stock. 8,146,900 options have been issued under the plan to date of which 7,157,038 have been exercised and 692,962 have expired to date. There were 296,900 options outstanding under the 2006 Plan on its expiration date of December 31, 2009. All options issued subsequent to this date were not issued pursuant to any plan.

Stock option activity during the three months ended March 31, 2018 and 2017 follows:

	Options Outstanding			Weighted Average Exercise Price		Weighted Average Grant-Date Fair Value		Weighted Average Remaining Contractual Life (Years)
Options outstanding at December 31, 2016		1,422,000		$	0.03	$	0.13		5.60
Options cancelled		(759,000	)		0.03		—
Options outstanding at March 31, 2017		663,000			0.03		0.13		4.12
Options outstanding at December 31, 2017		8,463,000		$	0.07	$	0.07		7.41
No option activity		—			—		—
Options outstanding at March 31, 2018		8,463,000		$	0.07	$	0.07		7.16

Options outstanding at March 31, 2018 consist of:

Date Issued	Number Outstanding		Number Exercisable		Exercise Price		Expiration Date
June 9, 2014		213,000		213,000	$	0.03	June 9, 2024
June 6, 2014		250,000		250,000	$	0.05	June 6, 2019
March 24, 2015		200,000		200,000	$	0.01	March 24, 2020
April 6, 2017		600,000		600,000	$	0.03	April 6, 2027
June 6, 2017		700,000		700,000	$	0.07	June 6, 2022
June 6, 2017		6,500,000		6,500,000	$	0.07	June 6, 2027
Total		8,463,000		8,463,000

Warrants

In addition to our 2006 Long Term Incentive Plan, we have issued and outstanding compensatory warrants to two consultants entitling the holders to purchase a total of 275,000 shares of our common stock at an average exercise price of $0.94 per share. Warrants to purchase 25,000 shares of common stock vest upon 6 months after the Company engages in an IPO, have an exercise price of $3.00 per share, and expire 2 years after the Company engages in an IPO. Warrants to purchase 250,000 shares of common stock vest 100,000 shares on issuance (June 1, 2009), and 50,000 shares on each of the following three anniversaries of the date of issuance, have exercise prices ranging from $0.50 per share to $1.15 per share, and expire on June 1, 2019. The issuance of the compensatory warrants was not submitted to our shareholders for their approval.

Warrant activity during the three months ended March 31, 2018 and 2017 follows:

	Warrants Outstanding		Weighted Average Exercise Price		Weighted Average Grant-Date Fair Value		⁽¹⁾Weighted Average Remaining Contractual Life (Years)
Warrants outstanding at December 31, 2016		275,000	$	0.94	$	0.10		2.42
Warrant granted		125,000		0.40		—
Warrants outstanding at March 31, 2017		400,000	$	0.62	$	0.10		4.03
Warrants outstanding at December 31, 2017		400,000	$	0.62	$	0.10		3.27
Warrant granted		750,000		0.05		—
Warrants outstanding at March 31, 2018		1,150,000	$	0.21	$	0.10		3.64

(1) Exclusive of 25,000 warrants expiring 2 years after initial IPO.

Warrants outstanding at March 31, 2018 consist of:

Date Issued	Number Outstanding		Number Exercisable		Exercise Price		Expiration Date
April 1, 2000		25,000		25,000	$	3.00	2 years after IPO
June 1, 2009		100,000		100,000	$	0.50	June 1, 2019
June 1, 2009		50,000		50,000	$	0.65	June 1, 2019
June 1, 2009		50,000		50,000	$	0.85	June 1, 2019
June 1, 2009		50,000		50,000	$	1.15	June 1, 2019
January 1, 2017		50,000		50,000	$	0.25	October 10, 2021
January 1, 2017		50,000		50,000	$	0.50	November 7, 2021
January 5, 2017		25,000		25,000	$	0.50	January 5, 2022
February 5, 2018		375,000		375,000	$	0.50	February 5, 2023
February 5, 2018		375,000		375,000	$	0.50	February 5, 2023
Total		1,150,000		1,150,000

Note 9 – Convertible Debt

Convertible Notes Payable

On April 3, 2017, the Company entered into a Convertible Promissory Note pursuant to which the Company borrowed in the aggregate principal amount of $125,000. The convertible note is due 12 months after issuance and bears interest at a rate of 12%. The Note is convertible into shares of common stock of the Company 180 days following the date of funding and thereafter. The conversion price shall be subject to a discount of 50%. The conversion price shall be determined on the basis of the lowest VWAP (Volume Weighted Average Price) of the Common Stock during the prior twenty (20) trading day period. The Investor will be limited to convert no more than 4.99% of the issued and outstanding Common Stock at the time of conversion at any one time. At any time during the period beginning on the date of the Note and ending on the date which is 180 days thereafter, the Company may repay the Note by paying an amount equal to the then outstanding amount multiplied by 135%. During the three months ended March 31, 2018, the noteholder converted the remaining principal balance of $39,000 and accrued interest of $9,826 to 2,591,087 shares of common stock.

On November 28, 2017, the Company issued an 8% convertible note in the aggregate principal amount of $103,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due September 5, 2018 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date.

On October 10, 2017, the Company issued an 8% convertible note in the aggregate principal amount of $78,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due July 15, 2018 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date.

On July 5, 2017, the Company issued an 8% convertible note in the aggregate principal amount of $63,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due April 15, 2018 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. During the three months ended March 31, 2018, the noteholder converted the principal balance of the note and accrued interest of $2,520 to 2,753,093 shares of common stock.

On January 10, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $120,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due January 10, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 15 trading day period ending on the latest complete trading day prior to the conversion date.

On January 16, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $63,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due October 30, 2018 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date.

On March 6, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $126,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due March 6, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the lowest trading price during the 20 trading day period ending on the latest complete trading day prior to and including the conversion date.

The Company recorded a debt discount related to identified embedded derivatives relating to conversion features and a reset provisions (see Note 10) based fair values as of the inception date of the Notes. The calculated debt discount equaled the face of the 8% note dated March 30, 2017 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 12% note and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated July 5, 2017 and was amortized through the date the convertible debt was fully extinguished. Interest expense on the convertible notes of $14,878 was recorded for the three months ended March 31, 2018.

Convertible Debentures

The Company issued convertible debentures to three individuals. The debentures are convertible into 75,000 shares of common stock for up to 5 years, at the holders’ option, at an exercise price of $.50 and $.25, respectively. The debentures mature on the earlier of the closing of a subsequent financing event by the Company resulting in gross proceeds of at least $10,000,000 or three years from the date of issuance. The debentures bear interest at a rate of 10%. A beneficial conversion feature was not recorded as the fair market value of the Company’s common stock was less than the exercise prices at the dates of issuance and through the end of the period. Interest expense on the convertible debentures of $1,829 and $1,801 was recorded for the three months ended March 31, 2018 and 2017, respectively.

Note 10 – Notes Payable

Notes payable at March 31, 2018 and December 31, 2017 consists of loans to HealthDatix from 3 individuals totaling $52,500, respectively. The loans do not bear interest and there are no specific terms for repayment.

Note 11 – Stock Transactions

Common Stock Issued

In connection with the convertible notes payable (see Note 9 above) the noteholders converted $102,000 of principal balance and $12,346 of accrued interest to 5,344,180 shares of common stock during the three months ended March 31, 2018. The stock issued was determined based on the terms of the convertible notes.

The Company sold 375,000 shares of common stock to an investor valued at $.02 per share on February 5, 2018 for proceeds of $7,500.

Note 12 - Income Taxes

A full valuation allowance was recorded against the Company’s net deferred tax assets. A valuation allowance must be established if it is more likely than not that the deferred tax assets will not be realized. This assessment is based upon consideration of available positive and negative evidence, which includes, among other things, the Company’s most recent results of operations and expected future profitability. Based on the Company’s cumulative losses in recent years, a full valuation allowance against the Company’s deferred tax assets has been established as Management believes that the Company will not realize the benefit of those deferred tax assets.

Note 13 – Concentrations and Credit Risk

Sales and Accounts Receivable

HealthDatix had sales to four customers which accounted for approximately 30%, 21%, 21%, and 19%, respectively of HealthDatix’s total sales for the three months ended March 31, 2018. One customer accounted for 100% of accounts receivable at March 31, 2018.

HealthDatix had sales to two customers which accounted for approximately 80% and 11%, respectively of HealthDatix’s total sales for the three months ended March 31, 2017. One customer accounted for 100% of accounts receivable at March 31, 2017.

Cash

Cash is maintained at a major financial institution. Accounts held at U.S. financial institutions are insured by the FDIC up to $250,000. Cash balances could exceed insured amounts at any given time, however, the Company has not experienced any such losses. The Company did not have any interest-bearing accounts at March 31, 2018 and December 31, 2017, respectively.

Note 14 – Related Party Transactions

Amounts Due to Related Parties

Amounts due to related parties with balances of $128,476 at March 31, 2018 and December 31, 2017, respectively, do not bear interest and are payable on demand. The Company’s former subsidiary, Arcmail owed amounts on a credit card that is guaranteed by the husband of the Company’s Executive Vice President, who was held personally responsible by the credit card company for the unpaid balance.

Note 15 – Commitments and Contingencies

Lease Commitment

The Company is obligated under two operating leases for its premises that expire at various times through February 28, 2019.

Total future minimum annual lease payments under the leases for the years ending December 31 are as follows:

2018	$	20,550
2019		3,380
	$	23,930

Rent expense of $7,048 and $5,591 was charged to continuing operations for the three months ended March 31, 2018 and 2017, respectively.

Rent expense of $10,807 was charged to discontinued operations for the three months ended March 31, 2017.

Employment Arrangements With Executive Officers

Effective April 1, 2017, in connection with the acquisition of HealthDatix Inc., the Company entered into employment agreements with Jerry Robinson, MaryJo Robinson, and Kathleen Shepherd each under a three-year term at a base salary of $75,000 per year, bonuses based upon objectives set by the Company, and participation in all benefit programs generally made available to HealthDatix employees. The employment agreements restrict the executive officers from engaging in certain competitive activities for the greater of 60 months from the date of the agreements or two years following the termination of their respective employment.

Note 16 – Subsequent Events

Common Stock Issued

On April 27, 2018, the Company sold 600,000 shares of common stock at $.025 per share to an investor for proceeds of $15,000.

Subsequent to the end of the period through the date of the report, various noteholders converted $64,000 of principal to 2,798,573 shares of the Company’s common stock.

Equity Financing Transaction

On May 3, 2018, the Company entered into a Convertible Promissory Note with an accredited investor pursuant to an exemption under section 4(a)(2) of the securities act of 1933, pursuant to which the investor agreed to lend and the Company agreed to repay the investor the aggregate principal amount of $83,500. The convertible note is due 12 months after issuance and bears interest at a rate of 8%. The Note is convertible into shares of common stock of the Company 180 days following the date of funding and thereafter. The conversion price shall be subject to a discount of 35%. The conversion price shall be determined on the basis of the average of the three lowest closing bid prices of the Common Stock during the prior twenty (20) trading day period.

Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations

FORWARD LOOKING STATEMENTS

This Form 10-Q includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included or incorporated by reference in this Form 10-Q which address activities, events or developments that the Company expects or anticipates will or may occur in the future, including such things as future capital expenditures (including the amount and nature thereof), finding suitable merger or acquisition candidates, expansion and growth of the Company’s business and operations, and other such matters are forward-looking statements. These statements are based on certain assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments as well as other factors it believes are appropriate in the circumstances.

Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. Factors that could adversely affect actual results and performance include, among others, potential fluctuations in quarterly operating results and expenses, government regulation, technology change and competition. Consequently, all of the forward-looking statements made in this Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequence to or effects on the Company or its business or operations. The Company assumes no obligations to update any such forward-looking statements.

INTRODUCTION

iGambit is a company focused on the medical technology markets. Our primary focus is the expansion of our medical technology business HealthDatix Inc.

HealthDatix is an end to end Software-as-a-Service solution that manages, reports, and analyzes critical data, enabling healthcare organizations to deliver positive patient outcomes. HealthDatix provides an opportunity for physicians to identify patients eligible for both “Annual Wellness Visits” (AWV) as well as “Chronic Care Management” both of which are reimbursed by Medicare.

Our WellDatix solution offers a fully-hosted cloud service for healthcare providers to conduct the Medicare Annual Wellness Visit (AWV) program to their Medicare patients providing the patient with a 5-10 year Personalized Preventive Plan and physician reports that meet all Medicare audit requirements. The AWV is a program that allows a physician to identify those patients that have 2+ chronic conditions that require additional screening and management.

Additionally, our CareDatix Chronic Care Management System, encompasses our FDA approved Electronic House Call system and Medicare covered platform, for continuous management of chronic care patients. The CareDatix platform can be tailored for individual care and health management of patients susceptible to chronic illness. The CareDatix platform is also designed to accumulate information from any TeleMedicine or wearable device.

Assets. At March 31, 2018, we had $3,183,563 in total assets, compared to $3,328,755 at December 31, 2017. The decrease in total assets was primarily due to amortization of intangible assets from the acquisition of our HealthDatix subsidiary.

Liabilities. At March 31, 2018, our total liabilities were $1,061,518 compared to $959,780 at December 31, 2017. Our current liabilities at March 31, 2018 consisted of accounts payable and accrued expenses of $295,593, accrued interest on notes payable of $18,775, amounts due to related parties of $128,476, deferred revenue of $5,375, notes payable of $52,500 and convertible debentures of $560,799, whereas our total liabilities at December 31, 2017 consisted of current liabilities including accounts payable and accrued expenses of $348,354, accrued interest on notes payable of $21,602, amounts due to related parties of $128,476, deferred revenue of $9,100, notes payable of $52,500, convertible debentures of $333,689 and derivative liability of $ 66,059.

Stockholders’ Equity. Our Stockholders’ Equity decreased to $2,122,045 at March 31, 2018 from $2,368,975 at December 31, 2017. This decrease was primarily due to an increase in accumulated deficit during the three months ended March 31, 2018.

Three Months Ended March 31, 2018 as Compared to Three Months Ended March 31, 2017

Revenues and Net Loss. We had $4,192 of revenue from our HealthDatix subsidiary and a net loss of $610,033 during the three months ended March 31, 2018, compared to revenue of $4,350 and a net loss of $242,074 for the three months ended March 31, 2017. The decrease in revenue was due primarily to the revenue generated by our HealthDatix subsidiary. We reported a loss of $66,937 from discontinued operations for the three months ended March 31, 2017.

General and Administrative Expenses. General and Administrative Expenses increased to $234,264 for the three months ended March 31, 2018 from $167,380 for the three months ended March 31, 2017. For the three months ended March 31, 2018 our General and Administrative Expenses consisted of corporate administrative expenses of $44,315, legal and accounting fees of $18,110, employee benefits expenses (health and life insurance) of $10,268, marketing expenses of $16,675, payroll expenses of $105,086, contract labor expense of $12,200, commissions and fees expenses of $21,000, and exchange filing fees of $6,610. For the three months ended March 31, 2017 our General and Administrative Expenses consisted of corporate administrative expenses of $40,324, legal and accounting fees of $36,600, employee benefits expenses (health and life insurance) of $12,665, marketing expenses of $16,666, payroll expenses of $34,483, consulting expenses of $8,025, commissions and fees expenses of $11,000, and exchange filing fees of $7,617. The increases from the three months ended March 31, 2017 to the three months ended March 31, 2018 relate primarily due to: (i) an increase in payroll expenses; (ii) an increase in commissions and fees expenses; (iii) an increase in contract labor expense; and (iv) an increase in general and administrative costs associated with the operation of our HealthDatix subsidiary. Costs associated with our officers’ salaries and the operation of our HealthDatix subsidiary are expected to increase going forward, as we expand the business operations of HealthDatix which would likely increase our corporate administrative expenses.

Other Income (Expense). We reported change in fair value of derivative liability of $118,101, loss on extinguishment of debt of $63,699, and interest expense of $16,264 for the three months ended March 31, 2018. We reported interest expense of $11,927 for the three months ended March 31, 2017.

Liquidity and Capital Resources

General

As reflected in the accompanying consolidated financial statements, at March 31, 2018, we had $60,245 of cash and stockholders’ equity of $2,122,045. At December 31, 2017, we had $9,449 of cash and stockholders’ equity of $2,368,975.

Our primary capital requirements in 2018 are likely to arise from the expansion of our HealthDatix operations. It is not possible to quantify those costs at this point in time, in that they depend on HealthDatix’s business opportunities and the state of the overall economy. We anticipate raising capital in the private markets to cover any such costs, though there can be no guaranty we will be able to do so on terms we deem to be acceptable. We do not have any plans at this point in time to obtain a line of credit or other loan facility from a commercial bank.

While we believe in the viability of our strategy to improve HealthDatix’s sales volume, and in our ability to raise additional funds, there can be no assurances that we will be able to fully effectuate our business plan.

We believe we will continue to increase our cash position and liquidity for the foreseeable future. We believe we have enough capital to fund our present operations.

Cash Flow Activity

Net cash used in operating activities was $273,204, for the three months ended March 31, 2018, compared to $124,715 for the three months ended March 31, 2017. Net cash used in continuing operating activities was $273,204 for the three months ended March 31, 2018, compared to $115,740 for the three months ended March 31, 2017. Our primary use of operating cash flows from continuing operating activities was from net losses of $610,033 and $242,074 for the three months ended March 31, 2018 and 2017, respectively. Additional contributing factors to the change were from depreciation expense of $432, amortization expense of $173,967, non-cash interest expense of $15,527, a loss on extinguishment of debt of $63,699, change in fair value of derivative liability of $118,101, a decrease in accounts receivable of $4,733, a decrease in prepaid expenses of $16,856, a decrease in accounts payable and accrued expenses of $52,761, and a decrease in deferred revenue $3,725. Net cash used in discontinued operating activities was $0 for the three months ended March 31, 2018 and $8,975 for the three months ended March 31, 2017. Cash used in discontinued operations was primarily from net losses of $66,937 from our ArcMail subsidiary for the three months ended March 31, 2017.

Net cash used in continuing investing activities was $0 for the three months ended March 31, 2018 and $20,416 for the three months ended March 31, 2017. For the three months ended March 31, 2017 the primary source of cash flows from investing activities was from cash received from the acquisition of our HealthDatix subsidiary. Net cash provided by discontinued investing activities was $0 for the three months ended March 31, 2018 and $31,636 for the three months ended March 31, 2017.

Net Cash provided by financing activities was $324,000 for the three months ended March 31, 2018 compared to $176,500 for the three months ended March 31, 2017. The cash flows provided by continuing financing activities for the three months ended March 31, 2018 was primarily from $309,000 in proceeds from convertible debentures and $15,000 in proceeds from the sale of stock. The cash flows provided by continuing financing activities for the three months ended March 31, 2017 was primarily from $100,000 in proceeds from convertible debentures, $100,000 in proceeds from the sale of stock and $492 in advances from related parties.

Plan of Operation and Funding

We expect that working capital requirements will continue to be funded through a combination of our existing funds and further issuances of securities. Our working capital requirements are expected to increase in line with the growth of our business. Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund our operations over the next twelve months. We have no lines of credit or other bank financing arrangements. Generally, we have financed operations to date through the proceeds of the private placement of equity and debt instruments. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses. We intend to finance these expenses with further issuances of securities, and debt issuances. Thereafter, we expect we will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders. Further, such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

Not Required.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q.

Based on this evaluation, our chief executive officer and chief financial officer concluded that, as of March 31, 2018, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings.

From time-to-time, the Company is involved in various civil actions as part of its normal course of business. The Company is not a party to any litigation that is material to ongoing operations as defined in Item 103 of Regulation S-K as of the period ended March 31, 2018.

Item 1A. Risk Factors.

Not required

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None

Item 3. Defaults upon Senior Securities.

None

Item 4. Removed and Reserved.

Item 5. Other Information.

None

Item 6. Exhibits

Exhibit No.	Description
31.1	Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (This exhibit shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.)
32.2	Certification of the Interim Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (This exhibit shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section. Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.)

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on May 15, 2018.

		iGambit Inc.

		/s/ John Salerno
		John Salerno
		Chief Executive Officer


		/s/ Elisa Luqman
		Elisa Luqman
		Chief Financial Officer and Principal Accounting Officer

EX-31.1 2 ex31_1.htm EXHIBIT 31.1

Exhibit 31.1

Chief Executive Officer Certification

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, John Salerno, certify that:

1. I have reviewed this quarterly report on Form 10-Q of iGambit Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

May 15, 2018		/s/ John Salerno
		John Salerno
		Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 ex31_2.htm EXHIBIT 31.2

Exhibit 31.2

Chief Financial Officer Certification

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Elisa Luqman, certify that:

1. I have reviewed this quarterly report on Form 10-Q of iGambit Inc.;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

May 15, 2018		/s/ Elisa Luqman
		Elisa Luqman
		Chief Financial Officer
		(Principal Financial Officer)

EX-32.1 4 ex32_1.htm EXHIBIT 32.1

Exhibit 32.1

WRITTEN STATEMENT OF THE CHIEF EXECUTIVE OFFICER
Pursuant to 18 U.S.C. Section 1350
As adopted pursuant to section 906 of the Sarbanes-Oxley act of 2002

Solely for the purposes of complying with 18 U.S.C. s.1350 as adopted pursuant to section 906 of the Sarbanes-Oxley act of 2002, I, the undersigned Chief Executive Officer of iGambit Inc. (the “Company”), hereby certify, based on my knowledge, that the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2018, (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

May 15, 2018		/s/ John Salerno
		John Salerno
		Chief Executive Officer
		(Principal Executive Officer)

EX-32.2 5 ex32_2.htm EXHIBIT 32.2

Exhibit 32.2

WRITTEN STATEMENT OF THE CHIEF FINANCIAL OFFICER
Pursuant to 18 U.S.C. Section 1350
As adopted pursuant to section 906 of the Sarbanes-Oxley act of 2002

Solely for the purposes of complying with 18 U.S.C. s.1350 as adopted pursuant to section 906 of the Sarbanes-Oxley act of 2002, I, the undersigned Chief Financial Officer of iGambit Inc. (the “Company”), hereby certify, based on my knowledge, that the Quarterly Report on Form 10-Q of the Company for the quarter ended March 31, 2018, (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

May 15, 2018		/s/ Elisa Luqman
		Elisa Luqman
		Chief Financial Officer
		(Principal Financial Officer)

EX-101.INS 6 igmb-20180331.xml XBRL INSTANCE FILE 0001479681 2018-03-31 0001479681 2017-12-31 0001479681 2018-01-01 2018-03-31 0001479681 2017-01-01 2017-03-31 0001479681 2018-05-15 0001479681 2017-03-31 0001479681 2016-12-31 0001479681 igmb:FDA510KClearanceMember 2018-01-01 2018-03-31 0001479681 igmb:TechnologylicenseMember 2018-01-01 2018-03-31 0001479681 us-gaap:InProcessResearchAndDevelopmentMember 2018-01-01 2018-03-31 0001479681 us-gaap:SegmentDiscontinuedOperationsMember 2018-01-01 2018-03-31 0001479681 us-gaap:SegmentDiscontinuedOperationsMember 2017-01-01 2017-03-31 0001479681 igmb:OfficeEquipmentAndFixturesMember us-gaap:MinimumMember 2018-01-01 2018-03-31 0001479681 igmb:OfficeEquipmentAndFixturesMember us-gaap:MaximumMember 2018-01-01 2018-03-31 0001479681 igmb:ComputerHardwareMember 2018-01-01 2018-03-31 0001479681 igmb:ComputerSoftwareMember 2018-01-01 2018-03-31 0001479681 igmb:DevelopmentEquipmentMember 2018-01-01 2018-03-31 0001479681 igmb:SoftwareMember 2018-01-01 2018-03-31 0001479681 us-gaap:CustomerContractsMember 2018-01-01 2018-03-31 0001479681 us-gaap:SegmentContinuingOperationsMember 2018-01-01 2018-03-31 0001479681 us-gaap:SegmentContinuingOperationsMember 2017-01-01 2017-03-31 0001479681 igmb:SoftwareMember 2018-03-31 0001479681 us-gaap:CustomerContractsMember 2018-03-31 0001479681 igmb:FDA510KClearanceMember 2018-03-31 0001479681 igmb:TechnologylicenseMember 2018-03-31 0001479681 us-gaap:InProcessResearchAndDevelopmentMember 2018-03-31 0001479681 us-gaap:StockOptionMember 2018-01-01 2018-03-31 0001479681 us-gaap:WarrantMember 2018-01-01 2018-03-31 0001479681 us-gaap:StockOptionMember 2017-01-01 2017-03-31 0001479681 us-gaap:WarrantMember 2017-01-01 2017-03-31 0001479681 igmb:Options1Member 2018-01-01 2018-03-31 0001479681 igmb:Options2Member 2018-01-01 2018-03-31 0001479681 igmb:Options3Member 2018-01-01 2018-03-31 0001479681 igmb:Options4Member 2018-01-01 2018-03-31 0001479681 igmb:Options5Member 2018-01-01 2018-03-31 0001479681 igmb:Options6Member 2018-01-01 2018-03-31 0001479681 igmb:Options1Member 2018-03-31 0001479681 igmb:Options2Member 2018-03-31 0001479681 igmb:Options3Member 2018-03-31 0001479681 igmb:Options4Member 2018-03-31 0001479681 igmb:Options5Member 2018-03-31 0001479681 igmb:Options6Member 2018-03-31 0001479681 igmb:Warrants1Member 2018-01-01 2018-03-31 0001479681 igmb:Warrants2Member 2018-01-01 2018-03-31 0001479681 igmb:Warrants3Member 2018-01-01 2018-03-31 0001479681 igmb:Warrants4Member 2018-01-01 2018-03-31 0001479681 igmb:Warrants5Member 2018-01-01 2018-03-31 0001479681 igmb:Warrants6Member 2018-01-01 2018-03-31 0001479681 igmb:Warrants7Member 2018-01-01 2018-03-31 0001479681 igmb:Warrants8Member 2018-01-01 2018-03-31 0001479681 igmb:Warrants1Member 2018-03-31 0001479681 igmb:Warrants2Member 2018-03-31 0001479681 igmb:Warrants3Member 2018-03-31 0001479681 igmb:Warrants4Member 2018-03-31 0001479681 igmb:Warrants5Member 2018-03-31 0001479681 igmb:Warrants6Member 2018-03-31 0001479681 igmb:Warrants7Member 2018-03-31 0001479681 igmb:Warrants8Member 2018-03-31 0001479681 us-gaap:SalesMember igmb:FirstCustomersMember 2018-01-01 2018-03-31 0001479681 us-gaap:SalesMember igmb:CustomersTwoMember 2018-01-01 2018-03-31 0001479681 us-gaap:AccountsReceivableMember igmb:OneCustomerMember 2018-01-01 2018-03-31 0001479681 us-gaap:SalesMember igmb:CustomersThreeMember 2018-01-01 2018-03-31 0001479681 us-gaap:SalesMember igmb:CustomersFourMember 2018-01-01 2018-03-31 0001479681 us-gaap:InvestorMember 2018-02-01 2018-02-05 0001479681 us-gaap:InvestorMember 2018-02-05 0001479681 igmb:Warrants9Member 2018-01-01 2018-03-31 0001479681 igmb:Warrants9Member 2018-03-31 0001479681 igmb:Warrants10Member 2018-01-01 2018-03-31 0001479681 igmb:Warrants10Member 2018-03-31 0001479681 igmb:InvestorOneMember 2018-02-01 2018-02-05 0001479681 igmb:InvestorOneMember 2018-02-05 0001479681 igmb:NoteholderMember igmb:PrincipalMember 2018-01-01 2018-03-31 0001479681 igmb:NoteholderMember igmb:AccruedInterestMember 2018-01-01 2018-03-31 0001479681 igmb:NoteholderMember 2018-01-01 2018-03-31 0001479681 us-gaap:AccountsReceivableMember igmb:OneCustomerMember 2017-01-01 2017-03-31 0001479681 us-gaap:SalesMember igmb:FirstCustomersMember 2017-01-01 2017-03-31 0001479681 us-gaap:SalesMember igmb:CustomersTwoMember 2017-01-01 2017-03-31 0001479681 us-gaap:SubsequentEventMember igmb:NoteholderMember igmb:PrincipalMember 2018-04-01 2018-04-27 0001479681 us-gaap:SubsequentEventMember us-gaap:InvestorMember 2018-04-01 2018-04-27 0001479681 us-gaap:SubsequentEventMember us-gaap:InvestorMember 2018-04-27 0001479681 igmb:SoftwareMember 2017-12-31 0001479681 us-gaap:CustomerContractsMember 2017-12-31 0001479681 igmb:FDA510KClearanceMember 2017-12-31 0001479681 igmb:TechnologylicenseMember 2017-12-31 0001479681 us-gaap:InProcessResearchAndDevelopmentMember 2017-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure 10-Q 2018-03-31 false iGambit, Inc. 0001479681 igmb --12-31 125089324 Smaller Reporting Company Yes No No 2018 Q1

52500

3413

3845

-66937

.001

100000000

400000000

122290751

116196571

132290751

126196571

432

213

4538

432

213

10000000

P5Y

P7Y

P5Y

P3Y

P5Y

P10Y

299

5375

9100

10964

3801771

156925

644846

1396000

1000000

604000

156925

644846

1396000

1000000

604000

707853

533886

3093918

3267885

173967

12745

9613000

1063000

8463000

1150000

663000

400000

8463000

663000

1422000

213000

250000

200000

600000

700000

6500000

0.07

0.03

0.05

0.01

0.03

0.07

0.13

P7Y4M28D

P5Y7M6D

759000

0.03

2014-06-09 2014-06-06 2015-03-24 2017-04-06 2017-06-06 2017-06-06

8463000

213000

250000

200000

600000

700000

6500000

2024-06-09 2019-06-06 2020-03-24 2027-04-06 2022-06-06 2027-06-06

1150000

400000

275000

0.21 0.62 0.62 0.94

0.10

0.1

0.10

P3Y3M8D

P2Y5M1D

750000

125000

0.05 0.4 P3Y7M21D P4Y11D

2000-04-01

2009-06-01

2017-01-01

2017-01-05

2018-02-05

1150000

25000

100000

50000

25000

375000

1150000

25000

100000

50000

25000

375000

3.00

0.50

0.65

0.85

1.15

0.25

0.50

2 years after IPO 1-Jun-19 1-Jun-19 1-Jun-19 1-Jun-19 10-Oct-21 7-Nov-21 5-Jan-22 5-Feb-23 5-Feb-23

14878

1829 1801

0.30

0.21

1.00

0.21

0.19

1.00

0.80

0.11

250000

20550

3380

23930

10807

7048

5591

7551

7119

25000

15000

.05

0.05

0.025

128476

43249

80822

92848

4537

326247

29462

386157

375000 375000 600000

Note 1 - Organization and Basis of Presentation   The consolidated financial statements presented are those of iGambit Inc., (the “Company”) and its wholly-owned subsidiaries, HealthDatix, Inc. (“HealthDatix”), Wala, Inc. doing business as Arcmail Technology (“ArcMail”) and Gotham Innovation Lab Inc. (“Gotham”). The Company is a holding company which seeks out acquisitions of operating companies in technology markets. HealthDatix, Inc. is engaged in the business of streamlining the process of managing information in the document-intensive medical field for customers throughout the United States. ArcMail provides email archive solutions to domestic and international businesses through hardware and software sales, support, and maintenance. Gotham was in the business of providing media technology services to real estate agents and brokers in the New York metropolitan area.   Interim Financial Statements   The following (a) condensed consolidated balance sheet as of December 31, 2017, which has been derived from audited financial statements, and (b) the unaudited condensed consolidated interim financial statements of the Company have been prepared in accordance with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2018 are not necessarily indicative of results that may be expected for the year ending December 31, 2018. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”) on April 17, 2018.   Business Acquisition   On February 14, 2017, the Company acquired Healthdatix, Inc., formerly known as HubCentrix, Inc. in accordance with a stock purchase agreement. Previously, the Company was focused on the technology markets. The Company has tailored its strategy to focus on pursuing specific medical technology strategies and objectives.  The acquisition of HealthDatix, provides the Company with its first medical technology, WellDatix, a proprietary platform that enables physicians to identify patients eligible for Annual Wellness Visits which are reimbursed by Medicare. This technology positions the Company to participate in the anticipated accelerated market needs of the physician community throughout the country. Pursuant to the stock purchase agreement, the total consideration paid for the outstanding capital stock of HealthDatix was $1,050,000 consisting of 15,000,000 shares of iGambit restricted common stock, valued at $.07 per share.   The results of operations of HealthDatix for the period February 14, 2017 to March 31, 2017 have been included in the consolidated statements of operations for the three months ended March 31, 2017. The following table presents unaudited pro forma results of operations of the Company and HealthDatix as if the acquisition had occurred at January 1, 2017. The pro forma condensed financial information is presented for informational purposes only. The unaudited pro forma results of operations are not necessarily indicative of results that would have occurred had the acquisition taken place at the beginning of the earliest period presented, or of future results.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="text-align: center">March 31,</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2017</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 71%">Pro forma revenue</td> <td style="width: 10%"> </td> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">7,600</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Pro forma gross profit</td> <td> </td> <td>$</td> <td style="text-align: right">7,413</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>Pro forma loss from operations</td> <td> </td> <td>$</td> <td style="text-align: right">(187,172</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Pro forma net loss</td> <td> </td> <td>$</td> <td style="text-align: right">(199,099</td> <td>)</td></tr> </table>   On April 5, 2017, the Company, through its wholly owned subsidiary HealthDatix, Inc. (“HealthDatix”) consummated the acquisition of certain assets of the CyberCare Health Network Division from EncounterCare Solutions Inc. (ECSL) in accordance with an Asset Purchase Agreement (the “Agreement”) by and among, HealthDatix, ECSL and the Company. Pursuant to the Agreement, ECSL will sell, convey, transfer and assign to HealthDatix certain assets (the “Assets”), and HealthDatix will purchase and accept from the ECSL all right, title and interest in and to the Assets in exchange for sixty million 60,000,000 shares of restricted common stock of iGambit.

Note 2 – Discontinued Operations   Sale of Business   Effective October 1, 2016, management decided to dispose of its subsidiary Arcmail and entered into a letter of intent on March 1, 2017 to sell Arcmail in a stock exchange to the CEO of Arcmail. On June 30, 2017, the Company completed the sale of ArcMail to Rory T. Welch, the CEO of Arcmail (“Welch”) in accordance with a Stock Purchase Agreement (the “Purchase Agreement”) by and between the Company and Welch.  Pursuant to the Stock Purchase, the total consideration paid for the outstanding capital stock of ArcMail is remittance of 10,000,000 shares of iGambit common stock previously issued to Welch.  As per the Purchase Agreement, the Company’s operations of ArcMail ended March 31, 2017 and Welch’s operation of the business was effective as of April 1, 2017. Arcmail’s operating loss for the three months ended March 31, 2017 has been included in loss from discontinued operations in the statements of operations for the year ended December 31, 2017.   On November 5, 2015, pursuant to an asset purchase agreement Gotham sold assets consisting of fixed assets, client and supplier lists, trade names, software, social media accounts and websites, and domain names to VHT, Inc., a Delaware corporation for a purchase price of $600,000. Gotham received $400,000 and commencing on January 29, 2016, VHT, Inc. shall pay twelve equal monthly installments of $16,667 on the last business day of each month (the “Installment Payments” and each, an “Installment Payment”), each Installment Payment to consist of (1) an earn-out payment of $10,000 (the “Earn-Out Payments” and each, an “Earn-Out Payment”), and (2) an additional payment of $6,667 (the “Additional Payments” and each, an “Additional Payment”); provided that VHT, Inc. shall only be required to make the Earn-Out Payments for as long as it maintains its relationship with Gotham’s major client, unless it is dissatisfied with VHT, Inc. The terms of the installment payments were fulfilled as of December 31, 2016.   The components of loss from discontinued operations presented in the consolidated statements of operations for the three months ended March 31, 2017 are presented as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 71%">Sales</td> <td style="width: 10%"> </td> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">386,157</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Cost of sales</td> <td> </td> <td> </td> <td style="text-align: right">(29,462</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>General and administrative expenses</td> <td> </td> <td> </td> <td style="text-align: right">(326,247</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Depreciation and amortization</td> <td> </td> <td> </td> <td style="text-align: right">(4,537</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 1pt">Interest expense</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(92,848</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Loss from discontinued operations</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(66,937</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>

Note 3 – Summary of Significant Accounting Policies   Principles of Consolidation   The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, HealthDatix, Inc., Wala, Inc. and Gotham Innovation Lab, Inc.  All intercompany accounts and transactions have been eliminated.   Use of Estimates in the Preparation of Financial Statements   The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.   Fair Value Measurements   The Company adopted the provisions of ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.   ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:   Level 1 – quoted prices in active markets for identical assets or liabilities   Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable   Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)   The estimated fair value of the derivative liability was calculated using the Black-Scholes option pricing model. The Company uses Level 3 inputs to value its derivative liabilities. The following table provides a reconciliation of the beginning and ending balances for the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains and losses for the three months ended March 31, 2018.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>Liabilities:</td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 71%">Balance of derivative liabilities - beginning of period</td> <td style="width: 10%"> </td> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">66,059</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Issued</td> <td> </td> <td> </td> <td style="text-align: right">43,249</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>Converted</td> <td> </td> <td> </td> <td style="text-align: right">(227,409</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Change in fair value of derivative liabilities</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">118,101</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 2.5pt">Balance of derivative liabilities - end of period</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Convertible Instruments   The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.   Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.  The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.   The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.   Revenue Recognition   iGambit is a holding company and has no sources of revenue.   HealthDatix’s revenues are derived primarily from its Software as a Service (SaaS) offerings that are rendered to healthcare providers.  HealthDatix recognizes revenues when the products or services have been provided or delivered, the fees charged are fixed or determinable, HealthDatix and its customers understand the specific nature and terms of the agreed upon transactions, and collectability is reasonably assured. Arcmail recognizes revenue from product sales when the following four revenue recognition criteria are met: persuasive evidence of an arrangement exists, an equipment order has been placed with the vendor, the selling price is fixed or determinable, and collectability is reasonably assured. Revenues from maintenance contracts covering multiple future periods are recognized during the current periods and deferred revenue is recorded for future periods and classified as current or noncurrent, depending on the terms of the contracts.   Gotham’s revenues were derived primarily from the sale of products and services rendered to real estate brokers.   Gotham recognized revenues when the services or products have been provided or delivered, the fees charged are fixed or determinable, Gotham and its customers understood the specific nature and terms of the agreed upon transactions, and collectability was reasonably assured.   Advertising Costs   The Company expenses advertising costs as incurred. Advertising costs from continuing operations for the three months ended March 31, 2018 and 2017 were $0 and $299, respectively.   Cash and Cash Equivalents   For purposes of reporting cash flows, cash and cash equivalents include checking and money market accounts and any highly liquid debt instruments purchased with a maturity of three months or less.   Accounts Receivable   The Company analyzes the collectability of accounts receivable from continuing operations each accounting period and adjusts its allowance for doubtful accounts accordingly.  A considerable amount of judgment is required in assessing the realization of accounts receivables, including the creditworthiness of each customer, current and historical collection history and the related aging of past due balances.  The Company evaluates specific accounts when it becomes aware of information indicating that a customer may not be able to meet its financial obligations due to deterioration of its financial condition, lower credit ratings, bankruptcy or other factors affecting the ability to render payment.    Inventories   Inventories consisting of finished products are stated at the lower of cost or market and are presented in assets from discontinued operations. Cost is determined on an average cost basis. Property and equipment and depreciation   Property and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 45%">Office equipment and fixtures</td> <td style="width: 10%"> </td> <td style="width: 1%"> </td> <td style="width: 43%; text-align: right">5 - 7 years</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Computer hardware</td> <td> </td> <td> </td> <td style="text-align: right">5 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>Computer software</td> <td> </td> <td> </td> <td style="text-align: right">3 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Development equipment</td> <td> </td> <td> </td> <td style="text-align: right">5 years</td> <td> </td></tr> </table> Amortization Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 45%">Software</td> <td style="width: 10%"> </td> <td style="width: 1%"> </td> <td style="width: 43%; text-align: right">5 years</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Technology license</td> <td> </td> <td> </td> <td style="text-align: right">5 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>Purchased in process R&D</td> <td> </td> <td> </td> <td style="text-align: right">Indefinite</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Customer contracts</td> <td> </td> <td> </td> <td style="text-align: right">10 years</td> <td> </td></tr> </table> Goodwill   Goodwill represents the excess of assets acquired over liabilities assumed of HealthDatix and the fair market value of the common shares issued by the Company for the acquisition of HealthDatix. In accordance with ASC Topic No. 350 “Intangibles – Goodwill and Other”), the goodwill is not being amortized, but instead will be subject to an annual assessment of impairment by applying a fair-value based test, and will be reviewed more frequently if current events and circumstances indicate a possible impairment. An impairment loss is charged to expense in the period identified. If indicators of impairment are present and future cash flows are not expected to be sufficient to recover the asset’s carrying amount, an impairment loss is charged to expense in the period identified. The Company recorded a full impairment of the Goodwill as of December 31, 2017.   Long-Lived Assets   The Company assesses the valuation of components of its property and equipment and other long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows.   Deferred Revenue   Deposits from customers included in discontinued operations are not recognized as revenues, but as liabilities, until the following conditions are met: revenues are realized when cash or claims to cash (receivable) are received in exchange for goods or services or when assets received in such exchange are readily convertible to cash or claim to cash or when such goods/services are transferred. When such income item is earned, the related revenue item is recognized, and the deferred revenue is reduced. To the extent revenues are generated from the Company’s support and maintenance services, the Company recognizes such revenues when services are completed and billed. The Company has received deposits from its various customers that have been recorded as deferred revenue and presented as current liabilities in the amount of $5,375 and $9,100 as of March 31, 2018 and December 31, 2017, respectively.   Stock-Based Compensation   The Company accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity, which requires the measurement of compensation expense for all share-based compensation granted to employees and non-employee directors at fair value on the date of grant and recognition of compensation expense over the related service period for awards expected to vest.  The Company uses the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing model requires the input of highly subjective assumptions including the expected stock price volatility of the Company’s common stock, the risk free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption related to forfeitures of such grants.  Changes in these subjective input assumptions can materially affect the fair value estimate of the Company’s stock options and warrants.   Income Taxes   The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.   The Company applies the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the Company’s financial statements. In accordance with this provision, tax positions must meet a more-likely-than-not recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position.

Note 4 – Going Concern   The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.  The Company has disposed of its operating subsidiary, and has an accumulated deficit of $10,258,602, and a working capital deficit of $977,231 at March 31, 2018. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time.  The Company’s continuation as a going concern is dependent upon its ability to obtain necessary equity financing and ultimately from generating revenues from its newly acquired subsidiary to continue operations. The Company expects that working capital requirements will continue to be funded through a combination of its existing funds and further issuances of securities. Working capital requirements are expected to increase in line with the growth of the business. Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund operations over the next twelve months. The Company has no lines of credit or other bank financing arrangements.   The Company has financed operations to date through the proceeds of a private placement of equity and debt instruments.  In connection with the Company’s business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses. The Company intends to finance these expenses with further issuances of securities, and debt issuances. Thereafter, the Company expects it will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to current stockholders. Further, such securities might have rights, preferences or privileges senior to common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, the Company may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict business operations.   The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 5 – Property and Equipment   Property and equipment are carried at cost and consist of the following at March 31, 2018 and December 31, 2017:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2017</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 58%">Office equipment and fixtures</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">10,964</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">10,964</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Less: Accumulated depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7,551</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7,119</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,413</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,845</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Depreciation expense of $432 and $213 was charged to continuing operations for the three months ended March 31, 2018 and 2017, respectively.   Depreciation expense of $0 and $4,538 was charged to discontinued operations for the three months ended March 31, 2018 and 2017, respectively.

Note 6 – Intangible Assets   Intangible assets from the acquisitions of HealthDatix and ECSL are carried at cost and consist of the following at March 31, 2018 and December 31, 2017:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"> 2018</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2017 </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Life</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 46%">Software</td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">156,925</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">156,925</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">5 years</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Customer contracts</td> <td> </td> <td> </td> <td style="text-align: right">644,846</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">644,846</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>FDA 510K clearance</td> <td> </td> <td> </td> <td style="text-align: right">1,396,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,396,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Technology license</td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 1pt">In process research and development</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">604,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">604,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">Indefinite</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,801,771</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,801,771</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 1pt">Less: Accumulated amortization</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">707,853</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">533,886</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,093,918</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,267,885</td> <td style="padding-bottom: 2.5pt"> </td> <td> </td> <td> </td> <td> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Amortization expense of $173,967 and $12,745 was charged to continuing operations for the three months ended March 31, 2018 and 2017, respectively.

Note 7 - Loss Per Common Share   The Company calculates net income (loss) per common share in accordance with ASC 260 “Earnings Per Share” (“ASC 260”). Basic and diluted net earnings (loss) per common share was determined by dividing net earnings (loss) applicable to common stockholders by the weighted average number of common shares outstanding during the period. The Company’s potentially dilutive shares, which include outstanding common stock options and common stock warrants, have not been included in the computation of diluted net loss per share for the three months ended March 31, 2018 and 2017 as the result would be anti-dilutive.     <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="7" style="text-align: center">Three Months Ended</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: black 1pt solid; text-align: center">March 31,</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2017</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 58%">Stock options</td> <td style="width: 8%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">8,463,000</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">663,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Stock warrants</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,150,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">400,000</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 2.5pt">Total shares excluded from calculation</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">9,613,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,063,000</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Note 8 – Stock Based Compensation   Options   In 2006, the Company adopted the 2006 Long-Term Incentive Plan (the "2006 Plan").   Awards granted under the 2006 Plan have a ten-year term and may be incentive stock options, non-qualified stock options or warrants. The awards are granted at an exercise price equal to the fair market value on the date of grant and generally vest over a three or four year period. The Plan expired on December 31, 2009, therefore as of December 31, 2016, there was no unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2006 plan.   The 2006 Plan provided for the granting of options to purchase up to 10,000,000 shares of common stock.  8,146,900 options have been issued under the plan to date of which 7,157,038 have been exercised and 692,962 have expired to date.  There were 296,900 options outstanding under the 2006 Plan on its expiration date of December 31, 2009. All options issued subsequent to this date were not issued pursuant to any plan.   Stock option activity during the three months ended March 31, 2018 and 2017 follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Options Outstanding</td> <td style="text-align: center"> </td> <td colspan="3"> Weighted Average Exercise Price</td> <td style="text-align: center"> </td> <td colspan="3"> Weighted Average Grant-Date  Fair Value</td> <td style="text-align: center"> </td> <td colspan="3"> Weighted Average Remaining Contractual Life (Years)</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 44%">Options outstanding at December 31, 2016</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1,422,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">0.03</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">0.13</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">5.60</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Options cancelled</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(759,000</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">0.03</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 2.5pt">Options outstanding at  March 31, 2017</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">663,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">0.03</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">0.13</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4.12</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Options outstanding at December 31, 2017</td> <td> </td> <td> </td> <td style="text-align: right">8,463,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.07</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.07</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7.41</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 1pt">No option activity</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Options outstanding at  March 31, 2018</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">8,463,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.07</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.07</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">7.16</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Options outstanding at March 31, 2018 consist of:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: center">Date Issued</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Number Outstanding</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Number Exercisable</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Expiration Date</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 22%; padding-left: 0.75pt">June 9, 2014</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">213,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">213,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">0.03</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 17%; padding-left: 0.75pt; text-align: right">June 9, 2024</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 0.75pt">June 6, 2014</td> <td> </td> <td> </td> <td style="text-align: right">250,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">250,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.05</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: right">June 6, 2019</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 0.75pt">March 24, 2015</td> <td> </td> <td> </td> <td style="text-align: right">200,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">200,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.01</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: right">March 24, 2020</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 0.75pt">April 6, 2017</td> <td> </td> <td> </td> <td style="text-align: right">600,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">600,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.03</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: right">April 6, 2027</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 0.75pt">June 6, 2017</td> <td> </td> <td> </td> <td style="text-align: right">700,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">700,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.07</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: right">June 6, 2022</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 0.75pt">June 6, 2017</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">6,500,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">6,500,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td>$</td> <td style="text-align: right">0.07</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; padding-left: 0.75pt; text-align: right">June 6, 2027</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">8,463,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">8,463,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"> </td></tr> </table>   Warrants   In addition to our 2006 Long Term Incentive Plan, we have issued and outstanding compensatory warrants to two consultants entitling the holders to purchase a total of 275,000 shares of our common stock at an average exercise price of $0.94 per share. Warrants to purchase 25,000 shares of common stock vest upon 6 months after the Company engages in an IPO, have an exercise price of $3.00 per share, and expire 2 years after the Company engages in an IPO. Warrants to purchase 250,000 shares of common stock vest 100,000 shares on issuance (June 1, 2009), and 50,000 shares on each of the following three anniversaries of the date of issuance, have exercise prices ranging from $0.50 per share to $1.15 per share, and expire on June 1, 2019. The issuance of the compensatory warrants was not submitted to our shareholders for their approval.   Warrant activity during the three months ended March 31, 2018 and 2017 follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Warrants Outstanding</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> Weighted Average Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Grant-Date Fair Value</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> (1)Weighted Average Remaining Contractual Life (Years)</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 44%">Warrants outstanding at December 31, 2016</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">275,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">0.94</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">0.10</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">2.42</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Warrant granted</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">125,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">0.40</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 2.5pt">Warrants outstanding at March 31, 2017</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">400,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.62</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.10</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4.03</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Warrants outstanding at December 31, 2017</td> <td> </td> <td> </td> <td style="text-align: right">400,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.62</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.10</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.27</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 1pt">Warrant granted</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">750,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">0.05</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Warrants outstanding at March 31, 2018</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,150,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.21</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.10</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">3.64</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> (1) Exclusive of 25,000 warrants expiring 2 years after initial IPO.   Warrants outstanding at March 31, 2018 consist of:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid"> Date Issued</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> Number Outstanding</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> Number Exercisable</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> Expiration Date</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 22%; padding-left: 0.75pt">April 1, 2000</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">25,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">25,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">3.00</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 17%; padding-left: 0.75pt; text-align: center">2 years after IPO</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 0.75pt">June 1, 2009</td> <td> </td> <td> </td> <td style="text-align: right">100,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">100,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.50</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: center">June 1, 2019</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 0.75pt">June 1, 2009</td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.65</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: center">June 1, 2019</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 0.75pt">June 1, 2009</td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.85</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: center">June 1, 2019</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 0.75pt">June 1, 2009</td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.15</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: center">June 1, 2019</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 0.75pt">January 1, 2017</td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.25</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: center">October 10, 2021</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 0.75pt">January 1, 2017</td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.50</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: center">November 7, 2021</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 0.75pt">January 5, 2017</td> <td> </td> <td> </td> <td style="text-align: right">25,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">25,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.50</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: center">January 5, 2022</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 0.75pt">February 5, 2018</td> <td> </td> <td> </td> <td style="text-align: right">375,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">375,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.50</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: center">February 5, 2023</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 0.75pt">February 5, 2018</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">375,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">375,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">0.50</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; padding-left: 0.75pt; text-align: center">February 5, 2023</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 1pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,150,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,150,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt; text-align: center"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt; text-align: center"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt; text-align: center"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt; text-align: center"> </td></tr> </table>

Note 9 – Convertible Debt   Convertible Notes Payable   On April 3, 2017, the Company entered into a Convertible Promissory Note pursuant to which the Company borrowed in the aggregate principal amount of $125,000. The convertible note is due 12 months after issuance and bears interest at a rate of 12%. The Note is convertible into shares of common stock of the Company 180 days following the date of funding and thereafter. The conversion price shall be subject to a discount of 50%. The conversion price shall be determined on the basis of the lowest VWAP (Volume Weighted Average Price) of the Common Stock during the prior twenty (20) trading day period. The Investor will be limited to convert no more than 4.99% of the issued and outstanding Common Stock at the time of conversion at any one time. At any time during the period beginning on the date of the Note and ending on the date which is 180 days thereafter, the Company may repay the Note by paying an amount equal to the then outstanding amount multiplied by 135%. During the three months ended March 31, 2018, the noteholder converted the remaining principal balance of $39,000 and accrued interest of $9,826 to 2,591,087 shares of common stock.   On November 28, 2017, the Company issued an 8% convertible note in the aggregate principal amount of $103,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due September 5, 2018 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date.   On October 10, 2017, the Company issued an 8% convertible note in the aggregate principal amount of $78,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due July 15, 2018 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date.   On July 5, 2017, the Company issued an 8% convertible note in the aggregate principal amount of $63,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due April 15, 2018 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. During the three months ended March 31, 2018, the noteholder converted the principal balance of the note and accrued interest of $2,520 to 2,753,093 shares of common stock.   On January 10, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $120,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due January 10, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 15 trading day period ending on the latest complete trading day prior to the conversion date.   On January 16, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $63,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due October 30, 2018 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date.   On March 6, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $126,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due March 6, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the lowest trading price during the 20 trading day period ending on the latest complete trading day prior to and including the conversion date.   The Company recorded a debt discount related to identified embedded derivatives relating to conversion features and a reset provisions (see Note 10) based fair values as of the inception date of the Notes. The calculated debt discount equaled the face of the 8% note dated March 30, 2017 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 12% note and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated July 5, 2017 and was amortized through the date the convertible debt was fully extinguished. Interest expense on the convertible notes of $14,878 was recorded for the three months ended March 31, 2018.   Convertible Debentures   The Company issued convertible debentures to three individuals. The debentures are convertible into 75,000 shares of common stock for up to 5 years, at the holders’ option, at an exercise price of $.50 and $.25, respectively. The debentures mature on the earlier of the closing of a subsequent financing event by the Company resulting in gross proceeds of at least $10,000,000 or three years from the date of issuance. The debentures bear interest at a rate of 10%. A beneficial conversion feature was not recorded as the fair market value of the Company’s common stock was less than the exercise prices at the dates of issuance and through the end of the period. Interest expense on the convertible debentures of $1,829 and $1,801 was recorded for the three months ended March 31, 2018 and 2017, respectively.

Note 10 – Notes Payable   Notes payable at March 31, 2018 and December 31, 2017 consists of loans to HealthDatix from 3 individuals totaling $52,500, respectively. The loans do not bear interest and there are no specific terms for repayment.

Note 11 – Stock Transactions   Common Stock Issued   In connection with the convertible notes payable (see Note 9 above) the noteholders converted $102,000 of principal balance and $12,346 of accrued interest to 5,344,180 shares of common stock during the three months ended March 31, 2018. The stock issued was determined based on the terms of the convertible notes.   The Company sold 375,000 shares of common stock to an investor valued at $.02 per share on February 5, 2018 for proceeds of $7,500.   The Company sold 375,000 shares of common stock to an investor valued at $.02 per share on February 5, 2018 for proceeds of $7,500.

Note 12 - Income Taxes   A full valuation allowance was recorded against the Company’s net deferred tax assets. A valuation allowance must be established if it is more likely than not that the deferred tax assets will not be realized. This assessment is based upon consideration of available positive and negative evidence, which includes, among other things, the Company’s most recent results of operations and expected future profitability. Based on the Company’s cumulative losses in recent years, a full valuation allowance against the Company’s deferred tax assets has been established as Management believes that the Company will not realize the benefit of those deferred tax assets.

Note 13 – Concentrations and Credit Risk   Sales and Accounts Receivable   HealthDatix had sales to four customers which accounted for approximately 30%, 21%, 21%, and 19%, respectively of HealthDatix’s total sales for the three months ended March 31, 2018. One customer accounted for 100% of accounts receivable at March 31, 2018.   HealthDatix had sales to two customers which accounted for approximately 80% and 11%, respectively of HealthDatix’s total sales for the three months ended March 31, 2017. One customer accounted for 100% of accounts receivable at March 31, 2017.   Cash   Cash is maintained at a major financial institution. Accounts held at U.S. financial institutions are insured by the FDIC up to $250,000. Cash balances could exceed insured amounts at any given time, however, the Company has not experienced any such losses. The Company did not have any interest-bearing accounts at March 31, 2018 and December 31, 2017, respectively.

Note 14 - Related Party Transactions   Amounts Due to Related Parties   Amounts due to related parties with balances of $128,476 at March 31, 2018 and December 31, 2017, respectively, do not bear interest and are payable on demand. The Company’s former subsidiary, Arcmail owed amounts on a credit card that is guaranteed by the husband of the Company’s Executive Vice President, who was held personally responsible by the credit card company for the unpaid balance.

Note 15 – Commitments and Contingencies   Lease Commitment   The Company is obligated under two operating leases for its premises that expire at various times through February 28, 2019.   Total future minimum annual lease payments under the leases for the years ending December 31 are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="background-color: silver"> <td style="vertical-align: top; width: 44%">2018</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 10%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 43%; text-align: right">20,550</td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top">2019</td> <td style="vertical-align: bottom; padding-bottom: 1pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right">3,380</td> <td style="vertical-align: bottom; padding-bottom: 1pt"> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom; padding-bottom: 2.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 2.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">23,930</td> <td style="vertical-align: bottom; padding-bottom: 2.5pt"> </td></tr> </table>   Rent expense of $7,048 and $5,591 was charged to continuing operations for the three months ended March 31, 2018 and 2017, respectively.   Rent expense of $10,807 was charged to discontinued operations for the three months ended March 31, 2017.   Employment Arrangements With Executive Officers   Effective April 1, 2017, in connection with the acquisition of HealthDatix Inc., the Company entered into employment agreements with Jerry Robinson, MaryJo Robinson, and Kathleen Shepherd each under a three-year term at a base salary of $75,000 per year, bonuses based upon objectives set by the Company, and participation in all benefit programs generally made available to HealthDatix employees. The employment agreements restrict the executive officers from engaging in certain competitive activities for the greater of 60 months from the date of the agreements or two years following the termination of their respective employment.

Note 16 – Subsequent Events   Common Stock Issued   On April 27, 2018, the Company sold 600,000 shares of common stock at $.025 per share to an investor for proceeds of $15,000.   Subsequent to the end of the period through the date of the report, various noteholders converted $64,000 of principal to 2,798,573 shares of the Company’s common stock.   Equity Financing Transaction   On May 3, 2018, the Company entered into a Convertible Promissory Note with an accredited investor pursuant to an exemption under section 4(a)(2) of the securities act of 1933, pursuant to which the investor agreed to lend and the Company agreed to repay the investor the aggregate principal amount of $83,500. The convertible note is due 12 months after issuance and bears interest at a rate of 8%. The Note is convertible into shares of common stock of the Company 180 days following the date of funding and thereafter. The conversion price shall be subject to a discount of 35%. The conversion price shall be determined on the basis of the average of the three lowest closing bid prices of the Common Stock during the prior twenty (20) trading day period.

-10258602

-9648569

13248356

12891348

132291

126196

1061518

959780

66059

560799

333689

5375

9100

128476

18775

21602

295593

348354

3183563

3328755

1945

3093918

3267885

84287

55080

22521

39377

1521

6254

60245

9449

1000000

2122045

2368975

3183563

3328755

121245294

48807434

-0.01

0.00

-0.01

0.00

-610033

-242074

-610033

-175137

-411969

-163210

234264

167380

-3738

4170

7930

180

4192

4350

15000

100000

309000

100000

11220

31636

-20416

0 29584

50000

-273204

-124715

-8975

-52761

18366

16856

17492

4733

-1250

800

15527

11031

173967

66937

-610033

-242074

324000

200492

-23992

324000

176500

50796

63005

60245

9449

73527

10522

Principles of Consolidation   The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, HealthDatix, Inc., Wala, Inc. and Gotham Innovation Lab, Inc.  All intercompany accounts and transactions have been eliminated.

Use of Estimates in the Preparation of Financial Statements   The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.

Convertible Instruments   The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.   Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.  The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption.   The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.

Revenue Recognition   iGambit is a holding company and has no sources of revenue.   HealthDatix’s revenues are derived primarily from its Software as a Service (SaaS) offerings that are rendered to healthcare providers.  HealthDatix recognizes revenues when the products or services have been provided or delivered, the fees charged are fixed or determinable, HealthDatix and its customers understand the specific nature and terms of the agreed upon transactions, and collectability is reasonably assured. Arcmail recognizes revenue from product sales when the following four revenue recognition criteria are met: persuasive evidence of an arrangement exists, an equipment order has been placed with the vendor, the selling price is fixed or determinable, and collectability is reasonably assured. Revenues from maintenance contracts covering multiple future periods are recognized during the current periods and deferred revenue is recorded for future periods and classified as current or noncurrent, depending on the terms of the contracts.   Gotham’s revenues were derived primarily from the sale of products and services rendered to real estate brokers.   Gotham recognized revenues when the services or products have been provided or delivered, the fees charged are fixed or determinable, Gotham and its customers understood the specific nature and terms of the agreed upon transactions, and collectability was reasonably assured.

Advertising Costs   The Company expenses advertising costs as incurred. Advertising costs from continuing operations for the three months ended March 31, 2018 and 2017 were $0 and $299, respectively.

Cash and Cash Equivalents   For purposes of reporting cash flows, cash and cash equivalents include checking and money market accounts and any highly liquid debt instruments purchased with a maturity of three months or less.

Accounts Receivable   The Company analyzes the collectability of accounts receivable from continuing operations each accounting period and adjusts its allowance for doubtful accounts accordingly.  A considerable amount of judgment is required in assessing the realization of accounts receivables, including the creditworthiness of each customer, current and historical collection history and the related aging of past due balances.  The Company evaluates specific accounts when it becomes aware of information indicating that a customer may not be able to meet its financial obligations due to deterioration of its financial condition, lower credit ratings, bankruptcy or other factors affecting the ability to render payment.

Inventories   Inventories consisting of finished products are stated at the lower of cost or market and are presented in assets from discontinued operations. Cost is determined on an average cost basis.

Property and equipment and depreciation   Property and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 45%">Office equipment and fixtures</td> <td style="width: 10%"> </td> <td style="width: 1%"> </td> <td style="width: 43%; text-align: right">5 - 7 years</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Computer hardware</td> <td> </td> <td> </td> <td style="text-align: right">5 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>Computer software</td> <td> </td> <td> </td> <td style="text-align: right">3 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Development equipment</td> <td> </td> <td> </td> <td style="text-align: right">5 years</td> <td> </td></tr> </table>

Amortization Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 45%">Software</td> <td style="width: 10%"> </td> <td style="width: 1%"> </td> <td style="width: 43%; text-align: right">5 years</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Technology license</td> <td> </td> <td> </td> <td style="text-align: right">5 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>Purchased in process R&D</td> <td> </td> <td> </td> <td style="text-align: right">Indefinite</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Customer contracts</td> <td> </td> <td> </td> <td style="text-align: right">10 years</td> <td> </td></tr> </table>

Goodwill   Goodwill represents the excess of assets acquired over liabilities assumed of HealthDatix and the fair market value of the common shares issued by the Company for the acquisition of HealthDatix. In accordance with ASC Topic No. 350 “Intangibles – Goodwill and Other”), the goodwill is not being amortized, but instead will be subject to an annual assessment of impairment by applying a fair-value based test, and will be reviewed more frequently if current events and circumstances indicate a possible impairment. An impairment loss is charged to expense in the period identified. If indicators of impairment are present and future cash flows are not expected to be sufficient to recover the asset’s carrying amount, an impairment loss is charged to expense in the period identified. The Company recorded a full impairment of the Goodwill as of December 31, 2017.

Long-Lived Assets   The Company assesses the valuation of components of its property and equipment and other long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows.

Deferred Revenue   Deposits from customers included in discontinued operations are not recognized as revenues, but as liabilities, until the following conditions are met: revenues are realized when cash or claims to cash (receivable) are received in exchange for goods or services or when assets received in such exchange are readily convertible to cash or claim to cash or when such goods/services are transferred. When such income item is earned, the related revenue item is recognized, and the deferred revenue is reduced. To the extent revenues are generated from the Company’s support and maintenance services, the Company recognizes such revenues when services are completed and billed. The Company has received deposits from its various customers that have been recorded as deferred revenue and presented as current liabilities in the amount of $5,375 and $9,100 as of March 31, 2018 and December 31, 2017, respectively.

Stock-Based Compensation   The Company accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity, which requires the measurement of compensation expense for all share-based compensation granted to employees and non-employee directors at fair value on the date of grant and recognition of compensation expense over the related service period for awards expected to vest.  The Company uses the Black-Scholes option pricing model to estimate the fair value of its stock options and warrants. The Black-Scholes option pricing model requires the input of highly subjective assumptions including the expected stock price volatility of the Company’s common stock, the risk free interest rate at the date of grant, the expected vesting term of the grant, expected dividends, and an assumption related to forfeitures of such grants.  Changes in these subjective input assumptions can materially affect the fair value estimate of the Company’s stock options and warrants.

Income Taxes   The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities, and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse.   The Company applies the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the Company’s financial statements. In accordance with this provision, tax positions must meet a more-likely-than-not recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position.

The unaudited pro forma results of operations are not necessarily indicative of results that would have occurred had the acquisition taken place at the beginning of the earliest period presented, or of future results.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="text-align: center">March 31,</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1pt; text-align: center"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2017</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 71%">Pro forma revenue</td> <td style="width: 10%"> </td> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">7,600</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Pro forma gross profit</td> <td> </td> <td>$</td> <td style="text-align: right">7,413</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>Pro forma loss from operations</td> <td> </td> <td>$</td> <td style="text-align: right">(187,172</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Pro forma net loss</td> <td> </td> <td>$</td> <td style="text-align: right">(199,099</td> <td>)</td></tr> </table>

The components of loss from discontinued operations presented in the consolidated statements of operations for the three months ended March 31, 2017 are presented as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 71%">Sales</td> <td style="width: 10%"> </td> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">386,157</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Cost of sales</td> <td> </td> <td> </td> <td style="text-align: right">(29,462</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>General and administrative expenses</td> <td> </td> <td> </td> <td style="text-align: right">(326,247</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Depreciation and amortization</td> <td> </td> <td> </td> <td style="text-align: right">(4,537</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 1pt">Interest expense</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(92,848</td> <td style="padding-bottom: 1pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Loss from discontinued operations</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(66,937</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table> Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 45%">Office equipment and fixtures</td> <td style="width: 10%"> </td> <td style="width: 1%"> </td> <td style="width: 43%; text-align: right">5 - 7 years</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Computer hardware</td> <td> </td> <td> </td> <td style="text-align: right">5 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>Computer software</td> <td> </td> <td> </td> <td style="text-align: right">3 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Development equipment</td> <td> </td> <td> </td> <td style="text-align: right">5 years</td> <td> </td></tr> </table> Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 45%">Software</td> <td style="width: 10%"> </td> <td style="width: 1%"> </td> <td style="width: 43%; text-align: right">5 years</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Technology license</td> <td> </td> <td> </td> <td style="text-align: right">5 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>Purchased in process R&D</td> <td> </td> <td> </td> <td style="text-align: right">Indefinite</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Customer contracts</td> <td> </td> <td> </td> <td style="text-align: right">10 years</td> <td> </td></tr> </table>

Property and equipment are carried at cost and consist of the following at March 31, 2018 and December 31, 2017:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2017</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 58%">Office equipment and fixtures</td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">10,964</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">10,964</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Less: Accumulated depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7,551</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">7,119</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,413</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,845</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Intangible assets from the acquisitions of HealthDatix and ECSL are carried at cost and consist of the following at March 31, 2018 and December 31, 2017:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center"> 2018</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2017 </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Life</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 46%">Software</td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">156,925</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">156,925</td> <td style="width: 1%"> </td> <td style="width: 5%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">5 years</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Customer contracts</td> <td> </td> <td> </td> <td style="text-align: right">644,846</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">644,846</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>FDA 510K clearance</td> <td> </td> <td> </td> <td style="text-align: right">1,396,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,396,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Technology license</td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,000,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5 years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 1pt">In process research and development</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">604,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">604,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">Indefinite</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,801,771</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,801,771</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 1pt">Less: Accumulated amortization</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">707,853</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">533,886</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td> </td> <td> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,093,918</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,267,885</td> <td style="padding-bottom: 2.5pt"> </td> <td> </td> <td> </td> <td> </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The Company’s potentially dilutive shares, which include outstanding common stock options and common stock warrants, have not been included in the computation of diluted net loss per share for the three months ended March 31, 2018 and 2017 as the result would be anti-dilutive.     <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="7" style="text-align: center">Three Months Ended</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: black 1pt solid; text-align: center">March 31,</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">2017</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 58%">Stock options</td> <td style="width: 8%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">8,463,000</td> <td style="width: 1%"> </td> <td style="width: 8%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">663,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Stock warrants</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,150,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">400,000</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 2.5pt">Total shares excluded from calculation</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">9,613,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,063,000</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Stock option activity during the three months ended March 31, 2018 and 2017 follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Options Outstanding</td> <td style="text-align: center"> </td> <td colspan="3"> Weighted Average Exercise Price</td> <td style="text-align: center"> </td> <td colspan="3"> Weighted Average Grant-Date  Fair Value</td> <td style="text-align: center"> </td> <td colspan="3"> Weighted Average Remaining Contractual Life (Years)</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 44%">Options outstanding at December 31, 2016</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">1,422,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">0.03</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">0.13</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">5.60</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Options cancelled</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(759,000</td> <td style="padding-bottom: 1pt">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">0.03</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 2.5pt">Options outstanding at  March 31, 2017</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">663,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">0.03</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">0.13</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4.12</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Options outstanding at December 31, 2017</td> <td> </td> <td> </td> <td style="text-align: right">8,463,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.07</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.07</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">7.41</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 1pt">No option activity</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Options outstanding at  March 31, 2018</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">8,463,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.07</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.07</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">7.16</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

Options outstanding at March 31, 2018 consist of:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid; text-align: center">Date Issued</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Number Outstanding</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Number Exercisable</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid; text-align: center">Expiration Date</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 22%; padding-left: 0.75pt">June 9, 2014</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">213,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">213,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">0.03</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 17%; padding-left: 0.75pt; text-align: right">June 9, 2024</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 0.75pt">June 6, 2014</td> <td> </td> <td> </td> <td style="text-align: right">250,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">250,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.05</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: right">June 6, 2019</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 0.75pt">March 24, 2015</td> <td> </td> <td> </td> <td style="text-align: right">200,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">200,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.01</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: right">March 24, 2020</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 0.75pt">April 6, 2017</td> <td> </td> <td> </td> <td style="text-align: right">600,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">600,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.03</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: right">April 6, 2027</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 0.75pt">June 6, 2017</td> <td> </td> <td> </td> <td style="text-align: right">700,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">700,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.07</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: right">June 6, 2022</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 0.75pt">June 6, 2017</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">6,500,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">6,500,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td>$</td> <td style="text-align: right">0.07</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; padding-left: 0.75pt; text-align: right">June 6, 2027</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">8,463,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">8,463,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt"> </td></tr> </table>

Warrant activity during the three months ended March 31, 2018 and 2017 follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Warrants Outstanding</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> Weighted Average Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Grant-Date Fair Value</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> (1)Weighted Average Remaining Contractual Life (Years)</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 44%">Warrants outstanding at December 31, 2016</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">275,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">0.94</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">0.10</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">2.42</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Warrant granted</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">125,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">0.40</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 2.5pt">Warrants outstanding at March 31, 2017</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">400,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.62</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.10</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">4.03</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Warrants outstanding at December 31, 2017</td> <td> </td> <td> </td> <td style="text-align: right">400,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.62</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.10</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3.27</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 1pt">Warrant granted</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">750,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">0.05</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">—  </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"> </td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Warrants outstanding at March 31, 2018</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,150,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.21</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.10</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">3.64</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> (1) Exclusive of 25,000 warrants expiring 2 years after initial IPO.

Warrants outstanding at March 31, 2018 consist of:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1pt solid"> Date Issued</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> Number Outstanding</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> Number Exercisable</td> <td style="padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: black 1pt solid"> Exercise Price</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> Expiration Date</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 22%; padding-left: 0.75pt">April 1, 2000</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">25,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 16%; text-align: right">25,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 15%; text-align: right">3.00</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 17%; padding-left: 0.75pt; text-align: center">2 years after IPO</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 0.75pt">June 1, 2009</td> <td> </td> <td> </td> <td style="text-align: right">100,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">100,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.50</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: center">June 1, 2019</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 0.75pt">June 1, 2009</td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.65</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: center">June 1, 2019</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 0.75pt">June 1, 2009</td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.85</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: center">June 1, 2019</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 0.75pt">June 1, 2009</td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">1.15</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: center">June 1, 2019</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 0.75pt">January 1, 2017</td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.25</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: center">October 10, 2021</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 0.75pt">January 1, 2017</td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">50,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.50</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: center">November 7, 2021</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 0.75pt">January 5, 2017</td> <td> </td> <td> </td> <td style="text-align: right">25,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">25,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.50</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: center">January 5, 2022</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-left: 0.75pt">February 5, 2018</td> <td> </td> <td> </td> <td style="text-align: right">375,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">375,000</td> <td> </td> <td> </td> <td>$</td> <td style="text-align: right">0.50</td> <td> </td> <td> </td> <td style="padding-left: 0.75pt; text-align: center">February 5, 2023</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt; padding-left: 0.75pt">February 5, 2018</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">375,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">375,000</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid">$</td> <td style="border-bottom: black 1pt solid; text-align: right">0.50</td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt"> </td> <td style="padding-bottom: 1pt; padding-left: 0.75pt; text-align: center">February 5, 2023</td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 1pt; padding-left: 10pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,150,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1,150,000</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt; text-align: center"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt; text-align: center"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt; text-align: center"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; padding-left: 0.75pt; text-align: center"> </td></tr> </table>

Total future minimum annual lease payments under the leases for the years ending December 31 are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="background-color: silver"> <td style="vertical-align: top; width: 44%">2018</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 10%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 43%; text-align: right">20,550</td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top">2019</td> <td style="vertical-align: bottom; padding-bottom: 1pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1pt"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: right">3,380</td> <td style="vertical-align: bottom; padding-bottom: 1pt"> </td></tr> <tr style="background-color: silver"> <td style="vertical-align: top"> </td> <td style="vertical-align: bottom; padding-bottom: 2.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 2.5pt"> </td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double">$</td> <td style="vertical-align: bottom; border-bottom: black 2.25pt double; text-align: right">23,930</td> <td style="vertical-align: bottom; padding-bottom: 2.5pt"> </td></tr> </table>

Fair Value Measurements   The Company adopted the provisions of ASC Topic 820, Fair Value Measurements and Disclosures, which defines fair value as used in numerous accounting pronouncements, establishes a framework for measuring fair value and expands disclosure of fair value measurements. The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk.   ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:   Level 1 – quoted prices in active markets for identical assets or liabilities   Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable   Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)   The estimated fair value of the derivative liability was calculated using the Black-Scholes option pricing model. The Company uses Level 3 inputs to value its derivative liabilities. The following table provides a reconciliation of the beginning and ending balances for the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains and losses for the three months ended March 31, 2018.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>Liabilities:</td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 71%">Balance of derivative liabilities - beginning of period</td> <td style="width: 10%"> </td> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">66,059</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Issued</td> <td> </td> <td> </td> <td style="text-align: right">43,249</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>Converted</td> <td> </td> <td> </td> <td style="text-align: right">(227,409</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Change in fair value of derivative liabilities</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">118,101</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 2.5pt">Balance of derivative liabilities - end of period</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The following table provides a reconciliation of the beginning and ending balances for the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains and losses for the three months ended March 31, 2018.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td>Liabilities:</td> <td> </td> <td colspan="3"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="width: 71%">Balance of derivative liabilities - beginning of period</td> <td style="width: 10%"> </td> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">66,059</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Issued</td> <td> </td> <td> </td> <td style="text-align: right">43,249</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td>Converted</td> <td> </td> <td> </td> <td style="text-align: right">(227,409</td> <td>)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1pt">Change in fair value of derivative liabilities</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">118,101</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: silver"> <td style="padding-bottom: 2.5pt">Balance of derivative liabilities - end of period</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">—  </td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

-199099

-187172

7413

7600

66059

-118101

-227409 43249 Indefinite 977231 P7Y1M27D P4Y1M13D

102000

12346

64000

5344180

2798573

P3Y

75000

3122045 3368975

-63699

16264

11927

-198064

-11927

408231

167380

-3725

492

102000 0 12346 0

737

896

-273204

-115740

EX-101.SCH 7 igmb-20180331.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONDENSED CONSOLIDATED TSTAMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Note 1 - Organization and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Note 2 - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Note 3 - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Note 4 - Going Concern link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Note 5 - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Note 6 - Intangible Assets link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Note 7 - Earnings (Loss) Per Common Share link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Note 8 - Stock Based Compensation link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Note 9 - Convertible Debt link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Note 10 - Note Payable link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Note 11 - Stock Transactions link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Note 12 - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Note 13 - Concentrations and Credit Risk link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Note 14 - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Note 15 - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Note 16 - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Note 1 - Organization and Basis of Presentation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Note 2 - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Note 5 - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Note 6 - Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Note 7 - Loss Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Note 8 - Stock Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Note 15 - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Note 1 - Organization and Basis of Presentation (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Note 2 - Discontinued Operations (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Narratives) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Note 4 - Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Note 5 - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Note 5 - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Note 6 - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - Note 6 - Intangible Assets (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - Note 7 - Loss Per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - Note 8 - Stock Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - Note 8 - Stock Based Compensation (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - Note 8 - Stock Based Compensation (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - Note 8 - Stock Based Compensation (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - Note 9 - Convertible Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - Note 10 - Note Payable (Details Narratives) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - Note 11 - Stock Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - Note 13 - Concentrations and Credit Risk (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - Note 14 - Related Party Transactions (Details Narratives) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - Note 15 - Commitments And Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - Note 17 - Commitments and Contingencies (Details Narratives) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - Note 16- Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 igmb-20180331_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 igmb-20180331_def.xml XBRL DEFINITION FILE EX-101.LAB 10 igmb-20180331_lab.xml XBRL LABEL FILE Finite-Lived Intangible Assets by Major Class [Axis] FDA 510K clearance Technology license In process research and development Operating Activities [Axis] Discontinued Operations [Member] Property, Plant and Equipment, Type [Axis] Office equipment and fixtures Range [Axis] Minimum Maximum Computer hardware Computer software Development equipment Software Customer contracts Continuing Operations [Member] Antidilutive Securities [Axis] Options Warrant Award Type [Axis] Options One Options Two Options Three Options Four Options Five Options Six Warrants One Warrants Two Warrants Three Warrants Four Warrants Five Warrants Six Warrants Seven Warrants Eight Concentration Risk Benchmark [Axis] Sales [Member] Customer [Axis] First Customers [Member] Customers two [Member] Accounts Receivable [Member] One Customer [Member] Customers Three[Member] Customers Four[Member] Related Party [Axis] Investor Warrants Nine Warrants Ten Investor One Short-term Debt, Type [Axis] Noteholder Debt Security Category [Axis] Principal Accrued interest Subsequent Event Type [Axis] Subsequent Event [Member] Document and Entity Information: Entity Registrant Name Document Type Document Period End Date Trading Symbol Amendment Flag Entity Central Index Key Current Fiscal Year End Date Entity Common Stock, Shares Outstanding Entity Filer Category Entity Current Reporting Status Entity Voluntary Filers Entity Well-known Seasoned Issuer Document Fiscal Year Focus Document Fiscal Period Focus Statement of Financial Position [Abstract] Assets Current assets Cash Accounts receivable, net Prepaid expenses and other current assets Total current assets Other assets Property and equipment, net Intangilbe assets, net Deposits Assets LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY) Current liabilities Accounts payable and accrued expenses Accrued interest on notes payable Amounts due to related parties Deferred revenue Notes payable Convertible debentures, net Derivative liability Total liabilities Stockholders' equity (deficiency) Preferred stock, $.001 par value; authorized - 100,000,000 shares; issued and outstanding - 0 shares in 2017 and 2016, respectively Common stock, $.001 par value; authorized - 400,000,000 shares; 132,290,751 and 126,196,571 shares issued and 122,290,751 and 116,196,571 shares outstanding (net of treasury shares) as of March 31, 2018 and December 31, 2017, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity (deficiency) before Treasury stock Less: Treasury stock; 10,000,000 shares, at cost Total stockholders' equity Liabilities and Equity Preferred stock, shares authorized Preferred stock, par value Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares outstanding Common stock, shares issued Treasury stock Income Statement [Abstract] Sales Cost of Sales Gross profit (loss) Operating Expenses General and Administrative Expense Amortization Total operating expenses Loss from operations Other income (expenses) Interest income Change in fair value of derivative liability Loss on extinguishment of debt Interest Expense Total other income (expenses) Loss from continuing operations Income (loss) from discontinued operations Net loss Basic and fully diluted loss per common share: Continuing operations Discontinued operations Net loss per common share Weighted average common shares outstanding - basic and fully diluted Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Loss from discontinued operations Net loss from continuing operations Adjustments to reconcile net loss to net cash used in operating activities Depreciation Non cash interest expense Stock-based compensation expense Loss on extinguishment of debt Change in fair value of derivative liability Changes in operating assets and liabilities: Accounts receivable Prepaid expenses and other current assets Accounts payable and accrued expenses Deferred revenue Net cash used in continuing operating activities Net cash used in discontinued operating activities NET CASH USED IN OPERATING ACTIVITIES CASH FLOWS FROM INVESTING ACTIVITIES: Preacquisition loans to subsidiary Cash acquired from acquisition of subsidiary Net cash used in continuing investing activities Net cash provided by discontinued investing activities NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of convertible debentures Proceeds from sale of common stock Proceeds from related party loans Net cash provided by continuing financing activities Net cash provided by discontinued financing activities NET CASH PROVIDED BY FINANCING ACTIVITIES NET INCREASE IN CASH CASH - BEGINNING OF PERIOD CASH - END OF PERIOD SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION: Cash paid during the period for Interest Non-cash investing and financing activities: Debt discount related to derivative liability Notes payable converted to common stock Common stock issued in payment of accrued interest Disclosure Text Block [Abstract] Note 1 - Organization and Basis of Presentation Note 2 - Discontinued Operations Note 3 - Summary of Significant Accounting Policies Note 4 -Going Concern Note 5 - Property and Equipment Note 6 - Intangible Assets Note 7 - Earnings Per Common Share Note 8 - Stock Based Compensation Note 9 - Convertible Debt Note 10 - Note Payable Note 12 - Stock Transactions Note 13 - Income Taxes Note 15 - Concentrations and Credit Risk Note 16 - Related Party Transactions Note 17 - Commitments and Contingencies Note 18 - Subsequent Events Policy Text Block [Abstract] EX-101.PRE 11 igmb-20180331_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2018	May 15, 2018
Document and Entity Information:
Entity Registrant Name	iGambit, Inc.
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Trading Symbol	igmb
Amendment Flag	false
Entity Central Index Key	0001479681
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		125,089,324
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q1

XML 13 R2.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Current assets
Cash	$ 60,245	$ 9,449
Accounts receivable, net	1,521	6,254
Prepaid expenses and other current assets	22,521	39,377
Total current assets	84,287	55,080
Other assets
Property and equipment, net	3,413	3,845
Intangilbe assets, net	3,093,918	3,267,885
Deposits	1,945	1,945
Assets	3,183,563	3,328,755
Current liabilities
Accounts payable and accrued expenses	295,593	348,354
Accrued interest on notes payable	18,775	21,602
Amounts due to related parties	128,476	128,476
Deferred revenue	5,375	9,100
Notes payable	52,500	52,500
Convertible debentures, net	560,799	333,689
Derivative liability		66,059
Total liabilities	1,061,518	959,780
Stockholders' equity (deficiency)
Preferred stock, $.001 par value; authorized - 100,000,000 shares; issued and outstanding - 0 shares in 2017 and 2016, respectively
Common stock, $.001 par value; authorized - 400,000,000 shares; 132,290,751 and 126,196,571 shares issued and 122,290,751 and 116,196,571 shares outstanding (net of treasury shares) as of March 31, 2018 and December 31, 2017, respectively	132,291	126,196
Additional paid-in capital	13,248,356	12,891,348
Accumulated deficit	(10,258,602)	(9,648,569)
Total stockholders' equity (deficiency) before Treasury stock	3,122,045	3,368,975
Less: Treasury stock; 10,000,000 shares, at cost	(1,000,000)	(1,000,000)
Total stockholders' equity	2,122,045	2,368,975
Liabilities and Equity	$ 3,183,563	$ 3,328,755

XML 14 R3.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, par value	$ .001	$ .001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ .001	$ .001
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares outstanding	122,290,751	116,196,571
Common stock, shares issued	132,290,751	126,196,571
Treasury stock	10,000,000	10,000,000

XML 15 R4.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
Sales	$ 4,192	$ 4,350
Cost of Sales	7,930	180
Gross profit (loss)	(3,738)	4,170
Operating Expenses
General and Administrative Expense	234,264	167,380
Amortization	173,967	0
Total operating expenses	408,231	167,380
Loss from operations	(411,969)	(163,210)
Other income (expenses)
Interest income	0	0
Change in fair value of derivative liability	(118,101)	0
Loss on extinguishment of debt	(63,699)	0
Interest Expense	(16,264)	(11,927)
Total other income (expenses)	(198,064)	(11,927)
Loss from continuing operations	(610,033)	(175,137)
Income (loss) from discontinued operations	0	(66,937)
Net loss	$ (610,033)	$ (242,074)
Basic and fully diluted loss per common share:
Continuing operations	$ (0.01)	$ 0.00
Discontinued operations	0.00	0.00
Net loss per common share	$ (0.01)	$ 0.00
Weighted average common shares outstanding - basic and fully diluted	121,245,294	48,807,434

XML 16 R5.htm IDEA: XBRL DOCUMENT

CONDENSED CONSOLIDATED TSTAMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (610,033)	$ (242,074)
Loss from discontinued operations	0	66,937
Net loss from continuing operations	(610,033)	(175,137)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	432	213
Amortization	173,967	0
Non cash interest expense	15,527	11,031
Stock-based compensation expense	0	800
Loss on extinguishment of debt	63,699	0
Change in fair value of derivative liability	118,101	0
Changes in operating assets and liabilities:
Accounts receivable	4,733	(1,250)
Prepaid expenses and other current assets	16,856	17,492
Accounts payable and accrued expenses	(52,761)	18,366
Deferred revenue	(3,725)	0
Net cash used in continuing operating activities	(273,204)	(115,740)
Net cash used in discontinued operating activities	0	(8,975)
NET CASH USED IN OPERATING ACTIVITIES	(273,204)	(124,715)
CASH FLOWS FROM INVESTING ACTIVITIES:
Preacquisition loans to subsidiary	0	(50,000)
Cash acquired from acquisition of subsidiary	0	29,584
Net cash used in continuing investing activities	0	(20,416)
Net cash provided by discontinued investing activities	0	31,636
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	0	11,220
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible debentures	309,000	100,000
Proceeds from sale of common stock	15,000	100,000
Proceeds from related party loans	0	492
Net cash provided by continuing financing activities	324,000	200,492
Net cash provided by discontinued financing activities	0	(23,992)
NET CASH PROVIDED BY FINANCING ACTIVITIES	324,000	176,500
NET INCREASE IN CASH	50,796	63,005
CASH - BEGINNING OF PERIOD	9,449	10,522
CASH - END OF PERIOD	60,245	73,527
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the period for Interest	737	896
Non-cash investing and financing activities:
Debt discount related to derivative liability	43,249	80,822
Notes payable converted to common stock	102,000	0
Common stock issued in payment of accrued interest	$ 12,346	$ 0

XML 17 R6.htm IDEA: XBRL DOCUMENT

Note 1 - Organization and Basis of Presentation

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Note 1 - Organization and Basis of Presentation

Note 1 - Organization and Basis of Presentation

Interim Financial Statements

Business Acquisition

	March 31,
	2017
Pro forma revenue	$	7,600
Pro forma gross profit	$	7,413
Pro forma loss from operations	$	(187,172	)
Pro forma net loss	$	(199,099	)

XML 18 R7.htm IDEA: XBRL DOCUMENT

Note 2 - Discontinued Operations

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Note 2 - Discontinued Operations

Note 2 – Discontinued Operations

Sale of Business

The components of loss from discontinued operations presented in the consolidated statements of operations for the three months ended March 31, 2017 are presented as follows:

Sales	$	386,157
Cost of sales		(29,462	)
General and administrative expenses		(326,247	)
Depreciation and amortization		(4,537	)
Interest expense		(92,848	)
Loss from discontinued operations	$	(66,937	)

XML 19 R8.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Note 3 - Summary of Significant Accounting Policies

Note 3 – Summary of Significant Accounting Policies

Principles of Consolidation

Use of Estimates in the Preparation of Financial Statements

Fair Value Measurements

Level 1 – quoted prices in active markets for identical assets or liabilities

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

Liabilities:
Balance of derivative liabilities - beginning of period	$	66,059
Issued		43,249
Converted		(227,409	)
Change in fair value of derivative liabilities		118,101
Balance of derivative liabilities - end of period	$	—

Convertible Instruments

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.

Revenue Recognition

iGambit is a holding company and has no sources of revenue.

Advertising Costs

The Company expenses advertising costs as incurred. Advertising costs from continuing operations for the three months ended March 31, 2018 and 2017 were $0 and $299, respectively.

Cash and Cash Equivalents

For purposes of reporting cash flows, cash and cash equivalents include checking and money market accounts and any highly liquid debt instruments purchased with a maturity of three months or less.

Accounts Receivable

Inventories

Inventories consisting of finished products are stated at the lower of cost or market and are presented in assets from discontinued operations. Cost is determined on an average cost basis.

Property and equipment and depreciation

Office equipment and fixtures			5 - 7 years
Computer hardware			5 years
Computer software			3 years
Development equipment			5 years

Amortization

Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows:

Software			5 years
Technology license			5 years
Purchased in process R&D			Indefinite
Customer contracts			10 years

Goodwill

Long-Lived Assets

Deferred Revenue

Stock-Based Compensation

Income Taxes

XML 20 R9.htm IDEA: XBRL DOCUMENT

Note 4 - Going Concern

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Note 4 -Going Concern

Note 4 – Going Concern

XML 21 R10.htm IDEA: XBRL DOCUMENT

Note 5 - Property and Equipment

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Note 5 - Property and Equipment

Note 5 – Property and Equipment

Property and equipment are carried at cost and consist of the following at March 31, 2018 and December 31, 2017:

	2018		2017
Office equipment and fixtures	$	10,964	$	10,964
Less: Accumulated depreciation		7,551		7,119
	$	3,413	$	3,845

Depreciation expense of $432 and $213 was charged to continuing operations for the three months ended March 31, 2018 and 2017, respectively.

Depreciation expense of $0 and $4,538 was charged to discontinued operations for the three months ended March 31, 2018 and 2017, respectively.

XML 22 R11.htm IDEA: XBRL DOCUMENT

Note 6 - Intangible Assets

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Note 6 - Intangible Assets

Note 6 – Intangible Assets

Intangible assets from the acquisitions of HealthDatix and ECSL are carried at cost and consist of the following at March 31, 2018 and December 31, 2017:

	2018		2017		Life
Software	$	156,925	$	156,925		5 years
Customer contracts		644,846		644,846		10 years
FDA 510K clearance		1,396,000		1,396,000		5 years
Technology license		1,000,000		1,000,000		5 years
In process research and development		604,000		604,000		Indefinite
		3,801,771		3,801,771
Less: Accumulated amortization		707,853		533,886
	$	3,093,918	$	3,267,885

Amortization expense of $173,967 and $12,745 was charged to continuing operations for the three months ended March 31, 2018 and 2017, respectively.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Note 7 - Earnings (Loss) Per Common Share

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Note 7 - Earnings Per Common Share

Note 7 - Loss Per Common Share

	Three Months Ended
	March 31,
	2018		2017
Stock options		8,463,000		663,000
Stock warrants		1,150,000		400,000
Total shares excluded from calculation		9,613,000		1,063,000

XML 24 R13.htm IDEA: XBRL DOCUMENT

Note 8 - Stock Based Compensation

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Note 8 - Stock Based Compensation

Note 8 – Stock Based Compensation

Options

Stock option activity during the three months ended March 31, 2018 and 2017 follows:

	Options Outstanding			Weighted Average Exercise Price		Weighted Average Grant-Date Fair Value		Weighted Average Remaining Contractual Life (Years)
Options outstanding at December 31, 2016		1,422,000		$	0.03	$	0.13		5.60
Options cancelled		(759,000	)		0.03		—
Options outstanding at March 31, 2017		663,000			0.03		0.13		4.12
Options outstanding at December 31, 2017		8,463,000		$	0.07	$	0.07		7.41
No option activity		—			—		—
Options outstanding at March 31, 2018		8,463,000		$	0.07	$	0.07		7.16

Options outstanding at March 31, 2018 consist of:

Date Issued	Number Outstanding		Number Exercisable		Exercise Price		Expiration Date
June 9, 2014		213,000		213,000	$	0.03	June 9, 2024
June 6, 2014		250,000		250,000	$	0.05	June 6, 2019
March 24, 2015		200,000		200,000	$	0.01	March 24, 2020
April 6, 2017		600,000		600,000	$	0.03	April 6, 2027
June 6, 2017		700,000		700,000	$	0.07	June 6, 2022
June 6, 2017		6,500,000		6,500,000	$	0.07	June 6, 2027
Total		8,463,000		8,463,000

Warrants

Warrant activity during the three months ended March 31, 2018 and 2017 follows:

	Warrants Outstanding		Weighted Average Exercise Price		Weighted Average Grant-Date Fair Value		⁽¹⁾Weighted Average Remaining Contractual Life (Years)
Warrants outstanding at December 31, 2016		275,000	$	0.94	$	0.10		2.42
Warrant granted		125,000		0.40		—
Warrants outstanding at March 31, 2017		400,000	$	0.62	$	0.10		4.03
Warrants outstanding at December 31, 2017		400,000	$	0.62	$	0.10		3.27
Warrant granted		750,000		0.05		—
Warrants outstanding at March 31, 2018		1,150,000	$	0.21	$	0.10		3.64

(1) Exclusive of 25,000 warrants expiring 2 years after initial IPO.

Warrants outstanding at March 31, 2018 consist of:

Date Issued	Number Outstanding		Number Exercisable		Exercise Price		Expiration Date
April 1, 2000		25,000		25,000	$	3.00	2 years after IPO
June 1, 2009		100,000		100,000	$	0.50	June 1, 2019
June 1, 2009		50,000		50,000	$	0.65	June 1, 2019
June 1, 2009		50,000		50,000	$	0.85	June 1, 2019
June 1, 2009		50,000		50,000	$	1.15	June 1, 2019
January 1, 2017		50,000		50,000	$	0.25	October 10, 2021
January 1, 2017		50,000		50,000	$	0.50	November 7, 2021
January 5, 2017		25,000		25,000	$	0.50	January 5, 2022
February 5, 2018		375,000		375,000	$	0.50	February 5, 2023
February 5, 2018		375,000		375,000	$	0.50	February 5, 2023
Total		1,150,000		1,150,000

XML 25 R14.htm IDEA: XBRL DOCUMENT

Note 9 - Convertible Debt

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Note 9 - Convertible Debt

Note 9 – Convertible Debt

Convertible Notes Payable

Convertible Debentures

XML 26 R15.htm IDEA: XBRL DOCUMENT

Note 10 - Note Payable

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Note 10 - Note Payable

Note 10 – Notes Payable

XML 27 R16.htm IDEA: XBRL DOCUMENT

Note 11 - Stock Transactions

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Note 12 - Stock Transactions

Note 11 – Stock Transactions

Common Stock Issued

The Company sold 375,000 shares of common stock to an investor valued at $.02 per share on February 5, 2018 for proceeds of $7,500.

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21506-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21553-112644

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21475-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21521-112644

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21484-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21538-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21488-112644

+ Details

XML 28 R17.htm IDEA: XBRL DOCUMENT

Note 12 - Income Taxes

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Note 13 - Income Taxes

Note 12 - Income Taxes

XML 29 R18.htm IDEA: XBRL DOCUMENT

Note 13 - Concentrations and Credit Risk

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Note 15 - Concentrations and Credit Risk

Note 13 – Concentrations and Credit Risk

Sales and Accounts Receivable

Cash

XML 30 R19.htm IDEA: XBRL DOCUMENT

Note 14 - Related Party Transactions

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Note 16 - Related Party Transactions

Note 14 - Related Party Transactions

Amounts Due to Related Parties

XML 31 R20.htm IDEA: XBRL DOCUMENT

Note 15 - Commitments and Contingencies

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Note 17 - Commitments and Contingencies

Note 15 – Commitments and Contingencies

Lease Commitment

The Company is obligated under two operating leases for its premises that expire at various times through February 28, 2019.

Total future minimum annual lease payments under the leases for the years ending December 31 are as follows:

2018	$	20,550
2019		3,380
	$	23,930

Rent expense of $7,048 and $5,591 was charged to continuing operations for the three months ended March 31, 2018 and 2017, respectively.

Rent expense of $10,807 was charged to discontinued operations for the three months ended March 31, 2017.

Employment Arrangements With Executive Officers

XML 32 R21.htm IDEA: XBRL DOCUMENT

Note 16 - Subsequent Events

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Note 18 - Subsequent Events

Note 16 – Subsequent Events

Common Stock Issued

On April 27, 2018, the Company sold 600,000 shares of common stock at $.025 per share to an investor for proceeds of $15,000.

Subsequent to the end of the period through the date of the report, various noteholders converted $64,000 of principal to 2,798,573 shares of the Company’s common stock.

Equity Financing Transaction

XML 33 R22.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2018

Policy Text Block [Abstract]

Principles of Consolidation

Principles of Consolidation

Use of Estimates in the Preparation of Financial Statements

Use of Estimates in the Preparation of Financial Statements

Fair Value Measurements

Fair Value Measurements

Level 1 – quoted prices in active markets for identical assets or liabilities

Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

Liabilities:
Balance of derivative liabilities - beginning of period	$	66,059
Issued		43,249
Converted		(227,409	)
Change in fair value of derivative liabilities		118,101
Balance of derivative liabilities - end of period	$	—

Convertible Instruments

Convertible Instruments

The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities.

Revenue Recognition

Revenue Recognition

iGambit is a holding company and has no sources of revenue.

Advertising Costs

Advertising Costs

The Company expenses advertising costs as incurred. Advertising costs from continuing operations for the three months ended March 31, 2018 and 2017 were $0 and $299, respectively.

Cash and Cash Equivalents

Cash and Cash Equivalents

For purposes of reporting cash flows, cash and cash equivalents include checking and money market accounts and any highly liquid debt instruments purchased with a maturity of three months or less.

Accounts Receivable

Accounts Receivable

Inventories

Inventories

Inventories consisting of finished products are stated at the lower of cost or market and are presented in assets from discontinued operations. Cost is determined on an average cost basis.

Property and equipment and depreciation

Property and equipment and depreciation

Office equipment and fixtures			5 - 7 years
Computer hardware			5 years
Computer software			3 years
Development equipment			5 years

Amortization

Amortization

Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows:

Software			5 years
Technology license			5 years
Purchased in process R&D			Indefinite
Customer contracts			10 years

Goodwill

Goodwill

Long-Lived Assets

Long-Lived Assets

Deferred Revenue

Deferred Revenue

Stock-Based Compensation

Stock-Based Compensation

Income Taxes

Income Taxes

XML 34 R23.htm IDEA: XBRL DOCUMENT

Note 1 - Organization and Basis of Presentation (Tables)

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Business Acquisition, Pro Forma Information

The unaudited pro forma results of operations are not necessarily indicative of results that would have occurred had the acquisition taken place at the beginning of the earliest period presented, or of future results.

	March 31,
	2017
Pro forma revenue	$	7,600
Pro forma gross profit	$	7,413
Pro forma loss from operations	$	(187,172	)
Pro forma net loss	$	(199,099	)

XML 35 R24.htm IDEA: XBRL DOCUMENT

Note 2 - Discontinued Operations (Tables)

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Components of loss from discontinued operations

The components of loss from discontinued operations presented in the consolidated statements of operations for the three months ended March 31, 2017 are presented as follows:

Sales	$	386,157
Cost of sales		(29,462	)
General and administrative expenses		(326,247	)
Depreciation and amortization		(4,537	)
Interest expense		(92,848	)
Loss from discontinued operations	$	(66,937	)

XML 36 R25.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Fair value assets and liabilities measured on recurring basis

The following table provides a reconciliation of the beginning and ending balances for the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains and losses for the three months ended March 31, 2018.

Liabilities:
Balance of derivative liabilities - beginning of period	$	66,059
Issued		43,249
Converted		(227,409	)
Change in fair value of derivative liabilities		118,101
Balance of derivative liabilities - end of period	$	—

Schedule of estimated lives of respective assets

Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows:

Office equipment and fixtures			5 - 7 years
Computer hardware			5 years
Computer software			3 years
Development equipment			5 years

Schedule of estimated lives of the respective assets

Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows:

Software			5 years
Technology license			5 years
Purchased in process R&D			Indefinite
Customer contracts			10 years

XML 37 R26.htm IDEA: XBRL DOCUMENT

Note 5 - Property and Equipment (Tables)

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Schedule of property, plant and equipment

Property and equipment are carried at cost and consist of the following at March 31, 2018 and December 31, 2017:

	2018		2017
Office equipment and fixtures	$	10,964	$	10,964
Less: Accumulated depreciation		7,551		7,119
	$	3,413	$	3,845

XML 38 R27.htm IDEA: XBRL DOCUMENT

Note 6 - Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Schedule of intangible assets

Intangible assets from the acquisitions of HealthDatix and ECSL are carried at cost and consist of the following at March 31, 2018 and December 31, 2017:

	2018		2017		Life
Software	$	156,925	$	156,925		5 years
Customer contracts		644,846		644,846		10 years
FDA 510K clearance		1,396,000		1,396,000		5 years
Technology license		1,000,000		1,000,000		5 years
In process research and development		604,000		604,000		Indefinite
		3,801,771		3,801,771
Less: Accumulated amortization		707,853		533,886
	$	3,093,918	$	3,267,885

XML 39 R28.htm IDEA: XBRL DOCUMENT

Note 7 - Loss Per Common Share (Tables)

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Computation of diluted net income (loss) per share

The Company’s potentially dilutive shares, which include outstanding common stock options and common stock warrants, have not been included in the computation of diluted net loss per share for the three months ended March 31, 2018 and 2017 as the result would be anti-dilutive.

	Three Months Ended
	March 31,
	2018		2017
Stock options		8,463,000		663,000
Stock warrants		1,150,000		400,000
Total shares excluded from calculation		9,613,000		1,063,000

XML 40 R29.htm IDEA: XBRL DOCUMENT

Note 8 - Stock Based Compensation (Tables)

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Schedule of stock option activities

Stock option activity during the three months ended March 31, 2018 and 2017 follows:

	Options Outstanding			Weighted Average Exercise Price		Weighted Average Grant-Date Fair Value		Weighted Average Remaining Contractual Life (Years)
Options outstanding at December 31, 2016		1,422,000		$	0.03	$	0.13		5.60
Options cancelled		(759,000	)		0.03		—
Options outstanding at March 31, 2017		663,000			0.03		0.13		4.12
Options outstanding at December 31, 2017		8,463,000		$	0.07	$	0.07		7.41
No option activity		—			—		—
Options outstanding at March 31, 2018		8,463,000		$	0.07	$	0.07		7.16

Schedule of stock options outstanding

Options outstanding at March 31, 2018 consist of:

Date Issued	Number Outstanding		Number Exercisable		Exercise Price		Expiration Date
June 9, 2014		213,000		213,000	$	0.03	June 9, 2024
June 6, 2014		250,000		250,000	$	0.05	June 6, 2019
March 24, 2015		200,000		200,000	$	0.01	March 24, 2020
April 6, 2017		600,000		600,000	$	0.03	April 6, 2027
June 6, 2017		700,000		700,000	$	0.07	June 6, 2022
June 6, 2017		6,500,000		6,500,000	$	0.07	June 6, 2027
Total		8,463,000		8,463,000

Schedule of Warrants, Activity

Warrant activity during the three months ended March 31, 2018 and 2017 follows:

	Warrants Outstanding		Weighted Average Exercise Price		Weighted Average Grant-Date Fair Value		⁽¹⁾Weighted Average Remaining Contractual Life (Years)
Warrants outstanding at December 31, 2016		275,000	$	0.94	$	0.10		2.42
Warrant granted		125,000		0.40		—
Warrants outstanding at March 31, 2017		400,000	$	0.62	$	0.10		4.03
Warrants outstanding at December 31, 2017		400,000	$	0.62	$	0.10		3.27
Warrant granted		750,000		0.05		—
Warrants outstanding at March 31, 2018		1,150,000	$	0.21	$	0.10		3.64

(1) Exclusive of 25,000 warrants expiring 2 years after initial IPO.

Schedule of Outstanding Warrants

Warrants outstanding at March 31, 2018 consist of:

Date Issued	Number Outstanding		Number Exercisable		Exercise Price		Expiration Date
April 1, 2000		25,000		25,000	$	3.00	2 years after IPO
June 1, 2009		100,000		100,000	$	0.50	June 1, 2019
June 1, 2009		50,000		50,000	$	0.65	June 1, 2019
June 1, 2009		50,000		50,000	$	0.85	June 1, 2019
June 1, 2009		50,000		50,000	$	1.15	June 1, 2019
January 1, 2017		50,000		50,000	$	0.25	October 10, 2021
January 1, 2017		50,000		50,000	$	0.50	November 7, 2021
January 5, 2017		25,000		25,000	$	0.50	January 5, 2022
February 5, 2018		375,000		375,000	$	0.50	February 5, 2023
February 5, 2018		375,000		375,000	$	0.50	February 5, 2023
Total		1,150,000		1,150,000

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 41 R30.htm IDEA: XBRL DOCUMENT

Note 15 - Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2018

Disclosure Text Block [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases

Total future minimum annual lease payments under the leases for the years ending December 31 are as follows:

2018	$	20,550
2019		3,380
	$	23,930

XML 42 R31.htm IDEA: XBRL DOCUMENT

Note 1 - Organization and Basis of Presentation (Details)	3 Months Ended
	Mar. 31, 2017 USD ($)
Disclosure Text Block [Abstract]
Pro forma revenue	$ 7,600
Pro forma gross profit	7,413
Pro forma loss from operations	(187,172)
Pro forma net loss	$ (199,099)

XML 43 R32.htm IDEA: XBRL DOCUMENT

Note 2 - Discontinued Operations (Details) - USD ($)	3 Months Ended
Note 2 - Discontinued Operations (Details) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Loss from discontinued operations	$ 0	$ (66,937)
Discontinued Operations [Member]
Sales		386,157
Cost of Sales		(29,462)
General and administrative expenses		(326,247)
Depreciation and amortization		(4,537)
Interest expense		(92,848)
Loss from discontinued operations		$ (66,937)

- Definition

Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

XML 44 R33.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Liabilities:
Balance of derivative liabilities - beginning of year	$ 66,059
Issued	43,249
Converted	(227,409)
Change in fair value of derivative liabilities	118,101	$ 0
Balance of derivative liabilities - end of year	$ 0

XML 45 R34.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Significant Accounting Policies (Details 1)	3 Months Ended
	Mar. 31, 2018
Office equipment and fixtures \| Minimum
Office equipment useful life	5 years
Office equipment and fixtures \| Maximum
Office equipment useful life	7 years
Computer hardware
Office equipment useful life	5 years
Computer software
Office equipment useful life	3 years
Development equipment
Office equipment useful life	5 years

XML 46 R35.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Significant Accounting Policies (Details 2)	3 Months Ended
	Mar. 31, 2018
Software
Intangible assets useful life	5 years
Technology license
Intangible assets useful life	5 years
Customer contracts
Intangible assets useful life	10 years
In process research and development
Intangible assets useful life	Indefinite

XML 47 R36.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Significant Accounting Policies (Details Narratives) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Disclosure Text Block [Abstract]
Advertising costs	$ 0	$ 299
Deferred revenue	$ 5,375		$ 9,100

XML 48 R37.htm IDEA: XBRL DOCUMENT

Note 4 - Going Concern (Details Narrative) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Disclosure Text Block [Abstract]
Accumulated deficit	$ (10,258,602)	$ (9,648,569)
Working capital deficit	$ 977,231

XML 49 R38.htm IDEA: XBRL DOCUMENT

Note 5 - Property and Equipment (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Disclosure Text Block [Abstract]
Office equipment and fixtures	$ 10,964	$ 10,964
Less: accumulated depreciation	7,551	7,119
Property, Plant and Equipment, Net	$ 3,413	$ 3,845

XML 50 R39.htm IDEA: XBRL DOCUMENT

Note 5 - Property and Equipment (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Depreciation expense	$ 432	$ 213
Continuing Operations [Member]
Depreciation expense	432	213
Discontinued Operations [Member]
Depreciation expense	$ 0	$ 4,538

XML 51 R40.htm IDEA: XBRL DOCUMENT

Note 6 - Intangible Assets (Details) - USD ($)	3 Months Ended
Note 6 - Intangible Assets (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Intangible Assets, Gross	$ 3,801,771	$ 3,801,771
Less: Accumulated amortization	707,853	533,886
Intangible Assets, Net	3,093,918	3,267,885
Software
Intangible Assets, Gross	$ 156,925	156,925
Intangible assets useful life	5 years
Customer contracts
Intangible Assets, Gross	$ 644,846	644,846
Intangible assets useful life	10 years
FDA 510K clearance
Intangible Assets, Gross	$ 1,396,000	1,396,000
Intangible assets useful life	5 years
Technology license
Intangible Assets, Gross	$ 1,000,000	1,000,000
Intangible assets useful life	5 years
In process research and development
Intangible Assets, Gross	$ 604,000	$ 604,000
Intangible assets useful life	Indefinite

XML 52 R41.htm IDEA: XBRL DOCUMENT

Note 6 - Intangible Assets (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Continuing Operations [Member]
Amortization expense	$ 173,967	$ 12,745

XML 53 R42.htm IDEA: XBRL DOCUMENT

Note 7 - Loss Per Common Share (Details) - shares	3 Months Ended
Note 7 - Loss Per Common Share (Details) - shares	Mar. 31, 2018	Mar. 31, 2017
Total shares excluded from calculation	9,613,000	1,063,000
Options
Total shares excluded from calculation	8,463,000	663,000
Warrant
Total shares excluded from calculation	1,150,000	400,000

XML 54 R43.htm IDEA: XBRL DOCUMENT

Note 8 - Stock Based Compensation (Details) - $ / shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disclosure Text Block [Abstract]
Options, Outstanding, Beginning Balance	8,463,000	1,422,000
Options, Outstanding, Beginning Balance, Weighted Average Exercise Price	$ 0.07	$ 0.03
Options, Outstanding, Beginning Balance, Weighted Average Grant-Date Fair Value	$ 0.07	$ 0.13
Options, Outstanding, Beginning Weighted Average Remaining Contractual Term	7 years 4 months 28 days	5 years 7 months 6 days
Options, Canceled		(759,000)
Options, Canceled, Weighted Average Exercise Price		$ 0.03
Options, Outstanding, Ending Balance	8,463,000	663,000
Options, Outstanding, Ending Balance, Weighted Average Exercise Price	$ 0.07	$ 0.03
Options, Outstanding, Ending Balance, Weighted Average Grant-Date Fair Value	$ 0.07	$ 0.13
Options, Outstanding, Ending Weighted Average Remaining Contractual Term	7 years 1 month 27 days	4 years 1 month 13 days

XML 55 R44.htm IDEA: XBRL DOCUMENT

Note 8 - Stock Based Compensation (Details 1) - $ / shares	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2016
Number of Outstanding	8,463,000	8,463,000	663,000	1,422,000
Number Exercisable	8,463,000
Exercise price	$ 0.07	$ 0.07	$ 0.03	$ 0.03
Options One
Issued Date	Jun. 09, 2014
Number of Outstanding	213,000
Number Exercisable	213,000
Exercise price	$ 0.03
Options outstanding Expiration Date	Jun. 09, 2024
Options Two
Issued Date	Jun. 06, 2014
Number of Outstanding	250,000
Number Exercisable	250,000
Exercise price	$ 0.05
Options outstanding Expiration Date	Jun. 06, 2019
Options Three
Issued Date	Mar. 24, 2015
Number of Outstanding	200,000
Number Exercisable	200,000
Exercise price	$ 0.01
Options outstanding Expiration Date	Mar. 24, 2020
Options Four
Issued Date	Apr. 06, 2017
Number of Outstanding	600,000
Number Exercisable	600,000
Exercise price	$ 0.03
Options outstanding Expiration Date	Apr. 06, 2027
Options Five
Issued Date	Jun. 06, 2017
Number of Outstanding	700,000
Number Exercisable	700,000
Exercise price	$ 0.07
Options outstanding Expiration Date	Jun. 06, 2022
Options Six
Issued Date	Jun. 06, 2017
Number of Outstanding	6,500,000
Number Exercisable	6,500,000
Exercise price	$ 0.07
Options outstanding Expiration Date	Jun. 06, 2027

XML 56 R45.htm IDEA: XBRL DOCUMENT

Note 8 - Stock Based Compensation (Details 2) - $ / shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Text Block [Abstract]
Warrants, Outstanding, Beginning Balance	400,000	275,000
Warrants, Outstanding, Beginning Balance, Weighted Average Exercise Price	$ 0.62	$ 0.94
Warrants, Outstanding, Beginning Balance, Weighted Average Grant-Date Fair Value	$ 0.1	$ 0.10
Warrants, Outstanding, Beginning Balance, Weighted Average Remaining Contractual Life	3 years 3 months 8 days	2 years 5 months 1 day
Warrants, Granted	750,000	125,000
Warrants, Granted, Weighted Average Exercise Price	$ 0.05	$ 0.4
Warrants, Outstanding, Ending Balance	1,150,000	400,000
Warrants, Outstanding, Ending Balance, Weighted Average Exercise Price	$ 0.21	$ 0.62
Warrants, Outstanding, Ending Balance, Weighted Average Grant-Date Fair Value	$ 0.10	$ 0.10
Warrants, Outstanding, Beginning Balance, Weighted Average Remaining Contractual Life	3 years 7 months 21 days	4 years 11 days

XML 57 R46.htm IDEA: XBRL DOCUMENT

Note 8 - Stock Based Compensation (Details 3)	3 Months Ended
Note 8 - Stock Based Compensation (Details 3)	Mar. 31, 2018 $ / shares shares
Number of Outstanding	1,150,000
Number Exercisable	1,150,000
Warrants One
Issued Date	Apr. 01, 2000
Number of Outstanding	25,000
Number Exercisable	25,000
Exercise price \| $ / shares	$ 3.00
Expiration Date	2 years after IPO
Warrants Two
Issued Date	Jun. 01, 2009
Number of Outstanding	100,000
Number Exercisable	100,000
Exercise price \| $ / shares	$ 0.50
Expiration Date	1-Jun-19
Warrants Three
Issued Date	Jun. 01, 2009
Number of Outstanding	50,000
Number Exercisable	50,000
Exercise price \| $ / shares	$ 0.65
Expiration Date	1-Jun-19
Warrants Four
Issued Date	Jun. 01, 2009
Number of Outstanding	50,000
Number Exercisable	50,000
Exercise price \| $ / shares	$ 0.85
Expiration Date	1-Jun-19
Warrants Five
Issued Date	Jun. 01, 2009
Number of Outstanding	50,000
Number Exercisable	50,000
Exercise price \| $ / shares	$ 1.15
Expiration Date	1-Jun-19
Warrants Six
Issued Date	Jan. 01, 2017
Number of Outstanding	50,000
Number Exercisable	50,000
Exercise price \| $ / shares	$ 0.25
Expiration Date	10-Oct-21
Warrants Seven
Issued Date	Jan. 01, 2017
Number of Outstanding	50,000
Number Exercisable	50,000
Exercise price \| $ / shares	$ 0.50
Expiration Date	7-Nov-21
Warrants Eight
Issued Date	Jan. 05, 2017
Number of Outstanding	25,000
Number Exercisable	25,000
Exercise price \| $ / shares	$ 0.50
Expiration Date	5-Jan-22
Warrants Nine
Issued Date	Feb. 05, 2018
Number of Outstanding	375,000
Number Exercisable	375,000
Exercise price \| $ / shares	$ 0.50
Expiration Date	5-Feb-23
Warrants Ten
Issued Date	Feb. 05, 2018
Number of Outstanding	375,000
Number Exercisable	375,000
Exercise price \| $ / shares	$ 0.50
Expiration Date	5-Feb-23

XML 58 R47.htm IDEA: XBRL DOCUMENT

Note 9 - Convertible Debt (Details Narrative) - USD ($)	3 Months Ended
Note 9 - Convertible Debt (Details Narrative) - USD ($)	Mar. 31, 2018	Mar. 31, 2017
Disclosure Text Block [Abstract]
Interest expense on the convertible notes	$ 14,878
Interest expense on the convertible debentures	$ 1,829	$ 1,801

XML 59 R48.htm IDEA: XBRL DOCUMENT

Note 10 - Note Payable (Details Narratives) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Disclosure Text Block [Abstract]
Notes payable from discontinued operations	$ 52,500	$ 52,500

XML 60 R49.htm IDEA: XBRL DOCUMENT

Note 11 - Stock Transactions (Details Narrative) - USD ($)		3 Months Ended
	Feb. 05, 2018	Mar. 31, 2018
Noteholder
Debt Conversion, Converted Instrument, Shares Issued		5,344,180
Noteholder \| Principal
Debt Conversion, Converted Instrument, Amount		$ 102,000
Noteholder \| Accrued interest
Debt Conversion, Converted Instrument, Amount		$ 12,346
Investor
Sale of common stock, Shares	375,000
Proceeds from common stock sold	$ 25,000
Sale of Stock price per share	$ .05
Investor One
Sale of common stock, Shares	375,000
Proceeds from common stock sold	$ 25,000
Sale of Stock price per share	$ 0.05

XML 61 R50.htm IDEA: XBRL DOCUMENT

Note 13 - Concentrations and Credit Risk (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
FDIC	$ 250,000
Sales [Member] \| First Customers [Member]
Concentration percentage	30.00%	80.00%
Sales [Member] \| Customers two [Member]
Concentration percentage	21.00%	11.00%
Sales [Member] \| Customers Three[Member]
Concentration percentage	21.00%
Sales [Member] \| Customers Four[Member]
Concentration percentage	19.00%
Accounts Receivable [Member] \| One Customer [Member]
Concentration percentage	100.00%	100.00%

XML 62 R51.htm IDEA: XBRL DOCUMENT

Note 14 - Related Party Transactions (Details Narratives) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Disclosure Text Block [Abstract]
Amounts due to related parties	$ 128,476	$ 128,476

XML 63 R52.htm IDEA: XBRL DOCUMENT

Note 15 - Commitments And Contingencies (Details)	Mar. 31, 2018 USD ($)
Commitments and Contingencies Disclosure [Abstract]
2018	$ 20,550
2019	3,380
Total	$ 23,930

XML 64 R53.htm IDEA: XBRL DOCUMENT

Note 17 - Commitments and Contingencies (Details Narratives) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Term	3 years
Base Salary	$ 75,000
Continuing Operations [Member]
Rent expense	$ 7,048	$ 5,591
Discontinued Operations [Member]
Rent expense		$ 10,807

XML 65 R54.htm IDEA: XBRL DOCUMENT

Note 16- Subsequent Events (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended
	Feb. 05, 2018	Apr. 27, 2018	Mar. 31, 2018
Investor
Sale of common stock	375,000
Proceeds from common stock sold	$ 25,000
Sale of Stock price per share	$ .05
Noteholder
Debt Conversion, Converted Instrument, Shares Issued			5,344,180
Noteholder \| Principal
Debt Conversion, Converted Instrument, Amount			$ 102,000
Subsequent Event [Member] \| Investor
Sale of common stock		600,000
Proceeds from common stock sold		$ 15,000
Sale of Stock price per share		$ 0.025
Subsequent Event [Member] \| Noteholder \| Principal
Debt Conversion, Converted Instrument, Amount		$ 64,000
Debt Conversion, Converted Instrument, Shares Issued		2,798,573

EXCEL 66 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 67 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 68 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 70 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 85 203 1 false 44 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://igambit.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://igambit.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://igambit.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://igambit.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - CONDENSED CONSOLIDATED TSTAMENTS OF CASH FLOWS (Unaudited) Sheet http://igambit.com/role/CondensedConsolidatedTstamentsOfCashFlows CONDENSED CONSOLIDATED TSTAMENTS OF CASH FLOWS (Unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - Note 1 - Organization and Basis of Presentation Sheet http://igambit.com/role/Note1-OrganizationAndBasisOfPresentation Note 1 - Organization and Basis of Presentation Notes 6 false false R7.htm 00000007 - Disclosure - Note 2 - Discontinued Operations Sheet http://igambit.com/role/Note2-DiscontinuedOperations Note 2 - Discontinued Operations Notes 7 false false R8.htm 00000008 - Disclosure - Note 3 - Summary of Significant Accounting Policies Sheet http://igambit.com/role/Note3-SummaryOfSignificantAccountingPolicies Note 3 - Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Note 4 - Going Concern Sheet http://igambit.com/role/Note4-GoingConcern Note 4 - Going Concern Notes 9 false false R10.htm 00000010 - Disclosure - Note 5 - Property and Equipment Sheet http://igambit.com/role/Note5-PropertyAndEquipment Note 5 - Property and Equipment Notes 10 false false R11.htm 00000011 - Disclosure - Note 6 - Intangible Assets Sheet http://igambit.com/role/Note6-IntangibleAssets Note 6 - Intangible Assets Notes 11 false false R12.htm 00000012 - Disclosure - Note 7 - Earnings (Loss) Per Common Share Sheet http://igambit.com/role/Note7-EarningsLossPerCommonShare Note 7 - Earnings (Loss) Per Common Share Notes 12 false false R13.htm 00000013 - Disclosure - Note 8 - Stock Based Compensation Sheet http://igambit.com/role/Note8-StockBasedCompensation Note 8 - Stock Based Compensation Notes 13 false false R14.htm 00000014 - Disclosure - Note 9 - Convertible Debt Sheet http://igambit.com/role/Note9-ConvertibleDebt Note 9 - Convertible Debt Notes 14 false false R15.htm 00000015 - Disclosure - Note 10 - Note Payable Sheet http://igambit.com/role/Note10-NotePayable Note 10 - Note Payable Notes 15 false false R16.htm 00000016 - Disclosure - Note 11 - Stock Transactions Sheet http://igambit.com/role/Note12-StockTransactions Note 11 - Stock Transactions Notes 16 false false R17.htm 00000017 - Disclosure - Note 12 - Income Taxes Sheet http://igambit.com/role/Note13-IncomeTaxes Note 12 - Income Taxes Notes 17 false false R18.htm 00000018 - Disclosure - Note 13 - Concentrations and Credit Risk Sheet http://igambit.com/role/Note15-ConcentrationsAndCreditRisk Note 13 - Concentrations and Credit Risk Notes 18 false false R19.htm 00000019 - Disclosure - Note 14 - Related Party Transactions Sheet http://igambit.com/role/Note16-RelatedPartyTransactions Note 14 - Related Party Transactions Notes 19 false false R20.htm 00000020 - Disclosure - Note 15 - Commitments and Contingencies Sheet http://igambit.com/role/Note17-CommitmentsAndContingencies Note 15 - Commitments and Contingencies Notes 20 false false R21.htm 00000021 - Disclosure - Note 16 - Subsequent Events Sheet http://igambit.com/role/Note17-SubsequentEvents Note 16 - Subsequent Events Notes 21 false false R22.htm 00000022 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Policies) Sheet http://igambit.com/role/Note3-SummaryOfSignificantAccountingPoliciesPolicies Note 3 - Summary of Significant Accounting Policies (Policies) Policies http://igambit.com/role/Note3-SummaryOfSignificantAccountingPolicies 22 false false R23.htm 00000023 - Disclosure - Note 1 - Organization and Basis of Presentation (Tables) Sheet http://igambit.com/role/Note1-OrganizationAndBasisOfPresentationTables Note 1 - Organization and Basis of Presentation (Tables) Tables http://igambit.com/role/Note1-OrganizationAndBasisOfPresentation 23 false false R24.htm 00000024 - Disclosure - Note 2 - Discontinued Operations (Tables) Sheet http://igambit.com/role/Note2-DiscontinuedOperationsTables Note 2 - Discontinued Operations (Tables) Tables http://igambit.com/role/Note2-DiscontinuedOperations 24 false false R25.htm 00000025 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Tables) Sheet http://igambit.com/role/Note3-SummaryOfSignificantAccountingPoliciesTables Note 3 - Summary of Significant Accounting Policies (Tables) Tables http://igambit.com/role/Note3-SummaryOfSignificantAccountingPolicies 25 false false R26.htm 00000026 - Disclosure - Note 5 - Property and Equipment (Tables) Sheet http://igambit.com/role/Note5-PropertyAndEquipmentTables Note 5 - Property and Equipment (Tables) Tables http://igambit.com/role/Note5-PropertyAndEquipment 26 false false R27.htm 00000027 - Disclosure - Note 6 - Intangible Assets (Tables) Sheet http://igambit.com/role/Note6-IntangibleAssetsTables Note 6 - Intangible Assets (Tables) Tables http://igambit.com/role/Note6-IntangibleAssets 27 false false R28.htm 00000028 - Disclosure - Note 7 - Loss Per Common Share (Tables) Sheet http://igambit.com/role/Note7-EarningsPerCommonShareTables Note 7 - Loss Per Common Share (Tables) Tables 28 false false R29.htm 00000029 - Disclosure - Note 8 - Stock Based Compensation (Tables) Sheet http://igambit.com/role/Note8-StockBasedCompensationTables Note 8 - Stock Based Compensation (Tables) Tables http://igambit.com/role/Note8-StockBasedCompensation 29 false false R30.htm 00000030 - Disclosure - Note 15 - Commitments and Contingencies (Tables) Sheet http://igambit.com/role/Note16-CommitmentsAndContingenciesTables Note 15 - Commitments and Contingencies (Tables) Tables http://igambit.com/role/Note17-CommitmentsAndContingencies 30 false false R31.htm 00000031 - Disclosure - Note 1 - Organization and Basis of Presentation (Details) Sheet http://igambit.com/role/Note1-OrganizationAndBasisOfPresentationDetails Note 1 - Organization and Basis of Presentation (Details) Details http://igambit.com/role/Note1-OrganizationAndBasisOfPresentationTables 31 false false R32.htm 00000032 - Disclosure - Note 2 - Discontinued Operations (Details) Sheet http://igambit.com/role/Note2-DiscontinuedOperationsDetails Note 2 - Discontinued Operations (Details) Details http://igambit.com/role/Note2-DiscontinuedOperationsTables 32 false false R33.htm 00000033 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details) Sheet http://igambit.com/role/Note3-SummaryOfSignificantAccountingPoliciesDetails Note 3 - Summary of Significant Accounting Policies (Details) Details http://igambit.com/role/Note3-SummaryOfSignificantAccountingPoliciesTables 33 false false R34.htm 00000034 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details 1) Sheet http://igambit.com/role/Note3-SummaryOfSignificantAccountingPoliciesDetails1 Note 3 - Summary of Significant Accounting Policies (Details 1) Details http://igambit.com/role/Note3-SummaryOfSignificantAccountingPoliciesTables 34 false false R35.htm 00000035 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details 2) Sheet http://igambit.com/role/Note3-SummaryOfSignificantAccountingPoliciesDetails2 Note 3 - Summary of Significant Accounting Policies (Details 2) Details http://igambit.com/role/Note3-SummaryOfSignificantAccountingPoliciesTables 35 false false R36.htm 00000036 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Narratives) Sheet http://igambit.com/role/Note3-SummaryOfSignificantAccountingPoliciesDetailsNarratives Note 3 - Summary of Significant Accounting Policies (Details Narratives) Details http://igambit.com/role/Note3-SummaryOfSignificantAccountingPoliciesTables 36 false false R37.htm 00000037 - Disclosure - Note 4 - Going Concern (Details Narrative) Sheet http://igambit.com/role/Note4-GoingConcernDetailsNarrative Note 4 - Going Concern (Details Narrative) Details http://igambit.com/role/Note4-GoingConcern 37 false false R38.htm 00000038 - Disclosure - Note 5 - Property and Equipment (Details) Sheet http://igambit.com/role/Note5-PropertyAndEquipmentDetails Note 5 - Property and Equipment (Details) Details http://igambit.com/role/Note5-PropertyAndEquipmentTables 38 false false R39.htm 00000039 - Disclosure - Note 5 - Property and Equipment (Details Narrative) Sheet http://igambit.com/role/Note5-PropertyAndEquipmentDetailsNarrative Note 5 - Property and Equipment (Details Narrative) Details http://igambit.com/role/Note5-PropertyAndEquipmentTables 39 false false R40.htm 00000040 - Disclosure - Note 6 - Intangible Assets (Details) Sheet http://igambit.com/role/Note6-IntangibleAssetsDetails Note 6 - Intangible Assets (Details) Details http://igambit.com/role/Note6-IntangibleAssetsTables 40 false false R41.htm 00000041 - Disclosure - Note 6 - Intangible Assets (Details Narrative) Sheet http://igambit.com/role/Note6-IntangibleAssetsDetailsNarrative Note 6 - Intangible Assets (Details Narrative) Details http://igambit.com/role/Note6-IntangibleAssetsTables 41 false false R42.htm 00000042 - Disclosure - Note 7 - Loss Per Common Share (Details) Sheet http://igambit.com/role/Note7-LossPerCommonShareDetails Note 7 - Loss Per Common Share (Details) Details http://igambit.com/role/Note7-EarningsPerCommonShareTables 42 false false R43.htm 00000043 - Disclosure - Note 8 - Stock Based Compensation (Details) Sheet http://igambit.com/role/Note8-StockBasedCompensationDetails Note 8 - Stock Based Compensation (Details) Details http://igambit.com/role/Note8-StockBasedCompensationTables 43 false false R44.htm 00000044 - Disclosure - Note 8 - Stock Based Compensation (Details 1) Sheet http://igambit.com/role/Note8-StockBasedCompensationDetails1 Note 8 - Stock Based Compensation (Details 1) Details http://igambit.com/role/Note8-StockBasedCompensationTables 44 false false R45.htm 00000045 - Disclosure - Note 8 - Stock Based Compensation (Details 2) Sheet http://igambit.com/role/Note8StockBasedCompensationDetails2 Note 8 - Stock Based Compensation (Details 2) Details http://igambit.com/role/Note8-StockBasedCompensationTables 45 false false R46.htm 00000046 - Disclosure - Note 8 - Stock Based Compensation (Details 3) Sheet http://igambit.com/role/Note8StockBasedCompensationDetails3 Note 8 - Stock Based Compensation (Details 3) Details http://igambit.com/role/Note8-StockBasedCompensationTables 46 false false R47.htm 00000047 - Disclosure - Note 9 - Convertible Debt (Details Narrative) Sheet http://igambit.com/role/Note9-ConvertibleDebtDetailsNarrative Note 9 - Convertible Debt (Details Narrative) Details http://igambit.com/role/Note9-ConvertibleDebt 47 false false R48.htm 00000048 - Disclosure - Note 10 - Note Payable (Details Narratives) Sheet http://igambit.com/role/Note11-NotePayableDetailsNarratives Note 10 - Note Payable (Details Narratives) Details http://igambit.com/role/Note10-NotePayable 48 false false R49.htm 00000049 - Disclosure - Note 11 - Stock Transactions (Details Narrative) Sheet http://igambit.com/role/Note12-StockTransactionsDetailsNarrative Note 11 - Stock Transactions (Details Narrative) Details http://igambit.com/role/Note12-StockTransactions 49 false false R50.htm 00000050 - Disclosure - Note 13 - Concentrations and Credit Risk (Details Narrative) Sheet http://igambit.com/role/Note15-ConcentrationsAndCreditRiskDetailsNarrative Note 13 - Concentrations and Credit Risk (Details Narrative) Details http://igambit.com/role/Note15-ConcentrationsAndCreditRisk 50 false false R51.htm 00000051 - Disclosure - Note 14 - Related Party Transactions (Details Narratives) Sheet http://igambit.com/role/Note16-RelatedPartyTransactionsDetailsNarratives Note 14 - Related Party Transactions (Details Narratives) Details http://igambit.com/role/Note16-RelatedPartyTransactions 51 false false R52.htm 00000052 - Disclosure - Note 15 - Commitments And Contingencies (Details) Sheet http://igambit.com/role/Note17-CommitmentsAndContingenciesDetails Note 15 - Commitments And Contingencies (Details) Details 52 false false R53.htm 00000053 - Disclosure - Note 17 - Commitments and Contingencies (Details Narratives) Sheet http://igambit.com/role/Note17-CommitmentsAndContingenciesDetailsNarratives Note 17 - Commitments and Contingencies (Details Narratives) Details 53 false false R54.htm 00000054 - Disclosure - Note 16- Subsequent Events (Details Narrative) Sheet http://igambit.com/role/Note16-SubsequentEventsDetailsNarrative Note 16- Subsequent Events (Details Narrative) Details 54 false false All Reports Book All Reports igmb-20180331.xml igmb-20180331.xsd igmb-20180331_cal.xml igmb-20180331_def.xml igmb-20180331_lab.xml igmb-20180331_pre.xml http://xbrl.sec.gov/dei/2014-01-31 http://fasb.org/us-gaap/2017-01-31 true true ZIP 72 0001607062-18-000172-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001607062-18-000172-xbrl.zip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